fbpx
Wikipedia

Progesterone

February 16, 2024

This article is about progesterone as a hormone. For its use as a medication, see progesterone (medication).

Progesterone (P4) is an endogenous steroid and progestogen sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species.[1][13] It belongs to a group of steroid hormones called the progestogens[13] and is the major progestogen in the body. Progesterone has a variety of important functions in the body. It is also a crucial metabolic intermediate in the production of other endogenous steroids, including the sex hormones and the corticosteroids, and plays an important role in brain function as a neurosteroid.[14]

Progesterone
Names
IUPAC name
Pregn-4-ene-3,20-dione[2][3]
Systematic IUPAC name
(1S,3aS,3bS,9aR,9bS,11aS)-1-Acetyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[a]phenanthren-7-one
Other names
P4;[1] Pregnenedione
Identifiers
  • 57-83-0 Y
3D model (JSmol)
  • Interactive image
ChEBI
  • CHEBI:17026 Y
ChEMBL
  • ChEMBL103 Y
ChemSpider
  • 5773 Y
DrugBank
  • DB00396 Y
ECHA InfoCard 100.000.318
KEGG
  • C00410 N
  • 5994
UNII
  • 4G7DS2Q64Y Y
  • DTXSID3022370
  • InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1 N
    Key: RJKFOVLPORLFTN-LEKSSAKUSA-N Y
  • CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
Properties
C21H30O2
Molar mass 314.469 g/mol
Melting point 126
log P 4.04[4]
Pharmacology
G03DA04 (WHO)
By mouth, topical/transdermal, vaginal, intramuscular injection, subcutaneous injection, subcutaneous implant
Pharmacokinetics:
OMP: <10%[5][6]
• Albumin: 80%
• CBG: 18%
• SHBG: <1%
• Free: 1–2%[7][8]
Hepatic (CYP2C19, CYP3A4, CYP2C9, 5α-reductase, 3α-HSDTooltip 3α-hydroxysteroid dehydrogenase, 17α-hydroxylase, 21-hydroxylase, 20α-HSDTooltip 20α-hydroxysteroid dehydrogenase)[9][10]
OMP: 16–18 hours[5][6][11]
IM: 22–26 hours[6][12]
SC: 13–18 hours[12]
Renal
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)

In addition to its role as a natural hormone, progesterone is also used as a medication, such as in combination with estrogen for contraception, to reduce the risk of uterine or cervical cancer, in hormone replacement therapy, and in feminizing hormone therapy.[15] It was first prescribed in 1934.[16]

Biological activity edit

See also: Pharmacodynamics of progesterone § Mechanism of action

Progesterone is the most important progestogen in the body. As a potent agonist of the nuclear progesterone receptor (nPR) (with an affinity of KD = 1 nM) the resulting effects on ribosomal transcription plays a major role in regulation of female reproduction.[13][17] In addition, progesterone is an agonist of the more recently discovered membrane progesterone receptors (mPRs),[18] of which the expression has regulation effects in reproduction function (oocyte maturation, labor, and sperm motility) and cancer although additional research is required to further define the roles.[19] It also functions as a ligand of the PGRMC1 (progesterone receptor membrane component 1) which impacts tumor progression, metabolic regulation, and viability control of nerve cells.[20][21][22] Moreover, progesterone is also known to be an antagonist of the sigma σ1 receptor,[23][24] a negative allosteric modulator of nicotinic acetylcholine receptors,[14] and a potent antagonist of the mineralocorticoid receptor (MR).[25] Progesterone prevents MR activation by binding to this receptor with an affinity exceeding even those of aldosterone and glucocorticoids such as cortisol and corticosterone,[25] and produces antimineralocorticoid effects, such as natriuresis, at physiological concentrations.[26] In addition, progesterone binds to and behaves as a partial agonist of the glucocorticoid receptor (GR), albeit with very low potency (EC50 >100-fold less relative to cortisol).[27][28]

Progesterone, through its neurosteroid active metabolites such as 5α-dihydroprogesterone and allopregnanolone, acts indirectly as a positive allosteric modulator of the GABAA receptor.[29]

Progesterone and some of its metabolites, such as 5β-dihydroprogesterone, are agonists of the pregnane X receptor (PXR),[30] albeit weakly so (EC50 >10 μM).[31] In accordance, progesterone induces several hepatic cytochrome P450 enzymes,[32] such as CYP3A4,[33][34] especially during pregnancy when concentrations are much higher than usual.[35] Perimenopausal women have been found to have greater CYP3A4 activity relative to men and postmenopausal women, and it has been inferred that this may be due to the higher progesterone levels present in perimenopausal women.[33]

Progesterone modulates the activity of CatSper (cation channels of sperm) voltage-gated Ca2+ channels. Since eggs release progesterone, sperm may use progesterone as a homing signal to swim toward eggs (chemotaxis). As a result, it has been suggested that substances that block the progesterone binding site on CatSper channels could potentially be used in male contraception.[36][37]

Biological function edit

 
During the menstrual cycle, levels of estradiol (an estrogen) vary by 200 percent. Levels of progesterone vary by over 1200 percent.[38]

Hormonal interactions edit

Progesterone has a number of physiological effects that are amplified in the presence of estrogens. Estrogens through estrogen receptors (ERs) induce or upregulate the expression of the PR.[39] One example of this is in breast tissue, where estrogens allow progesterone to mediate lobuloalveolar development.[40][41][42]

Elevated levels of progesterone potently reduce the sodium-retaining activity of aldosterone, resulting in natriuresis and a reduction in extracellular fluid volume. Progesterone withdrawal, on the other hand, is associated with a temporary increase in sodium retention (reduced natriuresis, with an increase in extracellular fluid volume) due to the compensatory increase in aldosterone production, which combats the blockade of the mineralocorticoid receptor by the previously elevated level of progesterone.[43]

Early sexual differentiation edit

Progesterone plays a role in early human sexual differentiation.[44] Placental progesterone is the feedstock for the 5α-dihydrotestosterone (DHT) produced via the backdoor pathway found operating in multiple non-gonadal tissues of the fetus,[45] whereas deficiencies in this pathway lead to undervirilization of the male fetus, resulting in incomplete development of the male genitalia.[46][47] DHT is a potent androgen that is responsible for the development of male genitalia, including the penis and scrotum.

During early fetal development, the undifferentiated gonads can develop into either testes or ovaries. The presence of the Y chromosome leads to the development of testes. The testes then produce testosterone, which is converted to DHT via the enzyme 5α-reductase. DHT is a potent androgen that is responsible for the masculinization of the external genitalia and the development of the prostate gland. Progesterone, produced by the placenta during pregnancy, plays a role in fetal sexual differentiation by serving as a precursor molecule for the synthesis of DHT via the backdoor pathway. In the absence of adequate levels of steroidogenic enzymes during fetal development, the backdoor pathway for DHT synthesis can become deficient, leading to undermasculinization of the male fetus. This can result in the development of ambiguous genitalia or even female genitalia in some cases. Therefore, both DHT and progesterone play crucial roles in early fetal sexual differentiation, with progesterone acting as a precursor molecule for DHT synthesis and DHT promoting the development of male genitalia.[44]

Reproductive system edit

 
Micrograph showing changes to the endometrium due to progesterone (decidualization) H&E stain.

Progesterone has key effects via non-genomic signalling on human sperm as they migrate through the female tract before fertilization occurs, though the receptor(s) as yet remain unidentified.[48] Detailed characterisation of the events occurring in sperm in response to progesterone has elucidated certain events including intracellular calcium transients and maintained changes,[49] slow calcium oscillations,[50] now thought to possibly regulate motility.[51] It is produced by the ovaries.[52] Progesterone has also been shown to demonstrate effects on octopus spermatozoa.[53]

Progesterone is sometimes called the "hormone of pregnancy",[54] and it has many roles relating to the development of the fetus:

  • Progesterone converts the endometrium to its secretory stage to prepare the uterus for implantation. At the same time progesterone affects the vaginal epithelium and cervical mucus, making it thick and impenetrable to sperm. Progesterone is anti-mitogenic in endometrial epithelial cells, and as such, mitigates the tropic effects of estrogen.[55] If pregnancy does not occur, progesterone levels will decrease, leading to menstruation. Normal menstrual bleeding is progesterone-withdrawal bleeding. If ovulation does not occur and the corpus luteum does not develop, levels of progesterone may be low, leading to anovulatory dysfunctional uterine bleeding.
  • During implantation and gestation, progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy.[56]
  • Progesterone decreases contractility of the uterine smooth muscle.[54] This effect contributes to prevention of preterm labor.[56] Studies have shown that in women who are pregnant with a single fetus, asymptomatic in the prenatal stage, and at a high risk of giving pre-term birth spontaneously, vaginal progesterone medication has been found to be effective in preventing spontaneous pre-term birth. Women who are at a high risk of giving pre-term birth spontaneously are those who have a short cervix of less than 25 mm or have previously given pre-term birth spontaneously. Although pre-term births are generally considered to be less than 37 weeks, these studies found that vaginal progesterone is associated with fewer pre-term births of less than 34 weeks.[57]
  • A drop in progesterone levels is possibly one step that facilitates the onset of labor.
  • In addition, progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production.

The fetus metabolizes placental progesterone in the production of adrenal steroids.[45]

Breasts edit

See also: Breast development § Biochemistry

Lobuloalveolar development edit

Progesterone plays an important role in breast development in women. In conjunction with prolactin, it mediates lobuloalveolar maturation of the mammary glands during pregnancy to allow for milk production and thus lactation and breastfeeding of offspring following parturition (childbirth).[58] Estrogen induces expression of the PR in breast tissue and hence progesterone is dependent on estrogen to mediate lobuloalveolar development.[40][41][42] It has been found that RANKLTooltip Receptor activator of nuclear factor kappa-B ligand is a critical downstream mediator of progesterone-induced lobuloalveolar maturation.[59] RANKL knockout mice show an almost identical mammary phenotype to PR knockout mice, including normal mammary ductal development but complete failure of the development of lobuloalveolar structures.[59]

Ductal development edit

Though to a far lesser extent than estrogen, which is the major mediator of mammary ductal development (via the ERα),[60][61] progesterone may be involved in ductal development of the mammary glands to some extent as well.[62] PR knockout mice or mice treated with the PR antagonist mifepristone show delayed although otherwise normal mammary ductal development at puberty.[62] In addition, mice modified to have overexpression of PRA display ductal hyperplasia,[59] and progesterone induces ductal growth in the mouse mammary gland.[62] Progesterone mediates ductal development mainly via induction of the expression of amphiregulin, the same growth factor that estrogen primarily induces the expression of to mediate ductal development.[62] These animal findings suggest that, while not essential for full mammary ductal development, progesterone seems to play a potentiating or accelerating role in estrogen-mediated mammary ductal development.[62]

Breast cancer risk edit

Progesterone also appears to be involved in the pathophysiology of breast cancer, though its role, and whether it is a promoter or inhibitor of breast cancer risk, has not been fully elucidated.[63][64] Most progestins, or synthetic progestogens, like medroxyprogesterone acetate, have been found to increase the risk of breast cancer in postmenopausal women in combination with estrogen as a component of menopausal hormone therapy.[65][64] The combination of natural oral progesterone or the atypical progestin dydrogesterone with estrogen has been associated with less risk of breast cancer than progestins plus estrogen.[66][67][68] However, this may simply be an artifact of the low progesterone levels produced with oral progesterone.[63][69] More research is needed on the role of progesterone in breast cancer.[64]

Skin health edit

The estrogen receptor, as well as the progesterone receptor, have been detected in the skin, including in keratinocytes and fibroblasts.[70][71] At menopause and thereafter, decreased levels of female sex hormones result in atrophy, thinning, and increased wrinkling of the skin and a reduction in skin elasticity, firmness, and strength.[70][71] These skin changes constitute an acceleration in skin aging and are the result of decreased collagen content, irregularities in the morphology of epidermal skin cells, decreased ground substance between skin fibers, and reduced capillaries and blood flow.[70][71] The skin also becomes more dry during menopause, which is due to reduced skin hydration and surface lipids (sebum production).[70] Along with chronological aging and photoaging, estrogen deficiency in menopause is one of the three main factors that predominantly influences skin aging.[70]

Hormone replacement therapy, consisting of systemic treatment with estrogen alone or in combination with a progestogen, has well-documented and considerable beneficial effects on the skin of postmenopausal women.[70][71] These benefits include increased skin collagen content, skin thickness and elasticity, and skin hydration and surface lipids.[70][71] Topical estrogen has been found to have similar beneficial effects on the skin.[70] In addition, a study has found that topical 2% progesterone cream significantly increases skin elasticity and firmness and observably decreases wrinkles in peri- and postmenopausal women.[71] Skin hydration and surface lipids, on the other hand, did not significantly change with topical progesterone.[71]

These findings suggest that progesterone, like estrogen, also has beneficial effects on the skin, and may be independently protective against skin aging.[71]

Sexuality edit

Libido edit

See also: Sexual motivation and hormones

Progesterone and its neurosteroid active metabolite allopregnanolone appear to be importantly involved in libido in females.[72]

Homosexuality edit

Dr. Diana Fleischman, of the University of Portsmouth, and colleagues looked for a relationship between progesterone and sexual attitudes in 92 women. Their research, published in the Archives of Sexual Behavior found that women who had higher levels of progesterone scored higher on a questionnaire measuring homoerotic motivation. They also found that men who had high levels of progesterone were more likely to have higher homoerotic motivation scores after affiliative priming compared to men with low levels of progesterone.[73][74][75][76]

Nervous system edit

Progesterone, like pregnenolone and dehydroepiandrosterone (DHEA), belongs to an important group of endogenous steroids called neurosteroids. It can be metabolized within all parts of the central nervous system.[77]

Neurosteroids are neuromodulators, and are neuroprotective, neurogenic, and regulate neurotransmission and myelination.[78] The effects of progesterone as a neurosteroid are mediated predominantly through its interactions with non-nuclear PRs, namely the mPRs and PGRMC1, as well as certain other receptors, such as the σ1 and nACh receptors.[79]

Brain damage edit

See also: Progesterone (medication) § Other uses

Previous studies have shown that progesterone supports the normal development of neurons in the brain, and that the hormone has a protective effect on damaged brain tissue. It has been observed in animal models that females have reduced susceptibility to traumatic brain injury and this protective effect has been hypothesized to be caused by increased circulating levels of estrogen and progesterone in females.[80]

Proposed mechanism edit

The mechanism of progesterone protective effects may be the reduction of inflammation that follows brain trauma and hemorrhage.[81][82]

Damage incurred by traumatic brain injury is believed to be caused in part by mass depolarization leading to excitotoxicity. One way in which progesterone helps to alleviate some of this excitotoxicity is by blocking the voltage-dependent calcium channels that trigger neurotransmitter release.[83] It does so by manipulating the signaling pathways of transcription factors involved in this release. Another method for reducing the excitotoxicity is by up-regulating the GABAA, a widespread inhibitory neurotransmitter receptor.[84]

Progesterone has also been shown to prevent apoptosis in neurons, a common consequence of brain injury.[85] It does so by inhibiting enzymes involved in the apoptosis pathway specifically concerning the mitochondria, such as activated caspase 3 and cytochrome c.

Not only does progesterone help prevent further damage, it has also been shown to aid in neuroregeneration.[86] One of the serious effects of traumatic brain injury includes edema. Animal studies show that progesterone treatment leads to a decrease in edema levels by increasing the concentration of macrophages and microglia sent to the injured tissue.[83][87] This was observed in the form of reduced leakage from the blood brain barrier in secondary recovery in progesterone treated rats. In addition, progesterone was observed to have antioxidant properties, reducing the concentration of oxygen free radicals faster than without.[84] There is also evidence that the addition of progesterone can also help remyelinate damaged axons due to trauma, restoring some lost neural signal conduction.[84] Another way progesterone aids in regeneration includes increasing the circulation of endothelial progenitor cells in the brain.[88] This helps new vasculature to grow around scar tissue which helps repair the area of insult.

Addiction edit

Progesterone enhances the function of serotonin receptors in the brain, so an excess or deficit of progesterone has the potential to result in significant neurochemical issues. This provides an explanation for why some people resort to substances that enhance serotonin activity such as nicotine, alcohol, and cannabis when their progesterone levels fall below optimal levels.[89]

  • Sex differences in hormone levels may induce women to respond differently than men to nicotine. When women undergo cyclic changes or different hormonal transition phases (menopause, pregnancy, adolescence), there are changes in their progesterone levels.[90] Therefore, females have an increased biological vulnerability to nicotine's reinforcing effects compared to males and progesterone may be used to counter this enhanced vulnerability. This information supports the idea that progesterone can affect behavior.[89]
  • Similar to nicotine, cocaine also increases the release of dopamine in the brain. The neurotransmitter is involved in the reward center and is one of the main neurotransmitters involved with substance abuse and reliance. In a study of cocaine users, it was reported that progesterone reduced craving and the feeling of being stimulated by cocaine. Thus, progesterone was suggested as an agent that decreases cocaine craving by reducing the dopaminergic properties of the drug.[91]

Societal edit

In a 2012 University of Amsterdam study of 120 women, women's luteal phase (higher levels of progesterone, and increasing levels of estrogen) was correlated with lower level of competitive behavior in gambling and math contest scenarios, while their premenstrual phase (sharply-decreasing levels of progesterone, and decreasing levels of estrogen) was correlated with a higher level of competitive behavior.[92]

Other effects edit

  • Progesterone also has a role in skin elasticity and bone strength, in respiration, in nerve tissue and in female sexuality, and the presence of progesterone receptors in certain muscle and fat tissue may hint at a role in sexually dimorphic proportions of those.[93][infringing link?]
  • During pregnancy, progesterone is said to decrease uterine irritability.[94]
  • During pregnancy, progesterone helps to suppress immune responses of the mother to fetal antigens, which prevents rejection of the fetus.[94]
  • Progesterone raises epidermal growth factor-1 (EGF-1) levels, a factor often used to induce proliferation, and used to sustain cultures, of stem cells.[95]
  • Progesterone increases core temperature (thermogenic function) during ovulation.[96][97]
  • Progesterone reduces spasm and relaxes smooth muscle. Bronchi are widened and mucus regulated. (PRs are widely present in submucosal tissue.)
  • Progesterone acts as an antiinflammatory agent and regulates the immune response.
  • Progesterone reduces gall-bladder activity.[98]
  • Progesterone normalizes blood clotting and vascular tone, zinc and copper levels, cell oxygen levels, and use of fat stores for energy.
  • Progesterone may affect gum health, increasing risk of gingivitis (gum inflammation).[99]
  • Progesterone appears to prevent endometrial cancer (involving the uterine lining) by regulating the effects of estrogen.
  • Progesterone plays an important role in the signaling of insulin release and pancreatic function, and may affect the susceptibility to diabetes or gestational diabetes.[100][101]
  • Progesterone levels in the blood were found to be lower in women who had higher weight and higher BMI among those who became pregnant through in vitro fertilization.[102]
  • Current data shows that micronized progesterone, which is chemically identical to the progesterone produced in women's bodies, in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism (blood clots in veins) and ischemic stroke (lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain). However, more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of myocardial infarctions (heart attacks).[103]
  • There have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause.[104]
  • Despite suggestions for using hormone therapy to prevent loss of muscle mass in post-menopausal women (50 and older), menopausal hormone therapy involving either estrogen alone or estrogen and progesterone has not been found to preserve muscle mass.[105] Menopausal hormone therapy also does not result in body weight reduction, BMI reduction, or change in glucose metabolism.[106]

Biochemistry edit

Biosynthesis edit

 
Steroidogenesis, showing progesterone among the progestogens in yellow area.[107]

In mammals, progesterone, like all other steroid hormones, is synthesized from pregnenolone, which itself is derived from cholesterol.

Cholesterol undergoes double oxidation to produce 22R-hydroxycholesterol and then 20α,22R-dihydroxycholesterol. This vicinal diol is then further oxidized with loss of the side chain starting at position C22 to produce pregnenolone. This reaction is catalyzed by cytochrome P450scc.

The conversion of pregnenolone to progesterone takes place in two steps. First, the 3β-hydroxyl group is oxidized to a keto group and second, the double bond is moved to C4, from C5 through a keto/enol tautomerization reaction.[108] This reaction is catalyzed by 3β-hydroxysteroid dehydrogenase/δ5-4-isomerase.

Progesterone in turn is the precursor of the mineralocorticoid aldosterone, and after conversion to 17α-hydroxyprogesterone, of cortisol and androstenedione. Androstenedione can be converted to testosterone, estrone, and estradiol, highlighting the critical role of progesterone in testosterone synthesis.

Pregnenolone and progesterone can also be synthesized by yeast.[109]

Approximately 25 mg of progesterone is secreted from the ovaries per day in women, while the adrenal glands produce about 2 mg of progesterone per day.[110]

Production rates, secretion rates, clearance rates, and blood levels of major sex hormones
Sex Sex hormone Reproductive
phase 		Blood
production rate 		Gonadal
secretion rate 		Metabolic
clearance rate 		Reference range (serum levels)
SI units Non-SI units
Men Androstenedione
–
 2.8 mg/day 1.6 mg/day 2200 L/day 2.8–7.3 nmol/L 80–210 ng/dL
Testosterone
–
 6.5 mg/day 6.2 mg/day 950 L/day 6.9–34.7 nmol/L 200–1000 ng/dL
Estrone
–
 150 μg/day 110 μg/day 2050 L/day 37–250 pmol/L 10–70 pg/mL
Estradiol
–
 60 μg/day 50 μg/day 1600 L/day <37–210 pmol/L 10–57 pg/mL
Estrone sulfate
–
 80 μg/day Insignificant 167 L/day 600–2500 pmol/L 200–900 pg/mL
Women Androstenedione
–
 3.2 mg/day 2.8 mg/day 2000 L/day 3.1–12.2 nmol/L 89–350 ng/dL
Testosterone
–
 190 μg/day 60 μg/day 500 L/day 0.7–2.8 nmol/L 20–81 ng/dL
Estrone Follicular phase 110 μg/day 80 μg/day 2200 L/day 110–400 pmol/L 30–110 pg/mL
Luteal phase 260 μg/day 150 μg/day 2200 L/day 310–660 pmol/L 80–180 pg/mL
Postmenopause 40 μg/day Insignificant 1610 L/day 22–230 pmol/L 6–60 pg/mL
Estradiol Follicular phase 90 μg/day 80 μg/day 1200 L/day <37–360 pmol/L 10–98 pg/mL
Luteal phase 250 μg/day 240 μg/day 1200 L/day 699–1250 pmol/L 190–341 pg/mL
Postmenopause 6 μg/day Insignificant 910 L/day <37–140 pmol/L 10–38 pg/mL
Estrone sulfate Follicular phase 100 μg/day Insignificant 146 L/day 700–3600 pmol/L 250–1300 pg/mL
Luteal phase 180 μg/day Insignificant 146 L/day 1100–7300 pmol/L 400–2600 pg/mL
Progesterone Follicular phase 2 mg/day 1.7 mg/day 2100 L/day 0.3–3 nmol/L 0.1–0.9 ng/mL
Luteal phase 25 mg/day 24 mg/day 2100 L/day 19–45 nmol/L 6–14 ng/mL
Notes and sources
Notes: "The concentration of a steroid in the circulation is determined by the rate at which it is secreted from glands, the rate of metabolism of precursor or prehormones into the steroid, and the rate at which it is extracted by tissues and metabolized. The secretion rate of a steroid refers to the total secretion of the compound from a gland per unit time. Secretion rates have been assessed by sampling the venous effluent from a gland over time and subtracting out the arterial and peripheral venous hormone concentration. The metabolic clearance rate of a steroid is defined as the volume of blood that has been completely cleared of the hormone per unit time. The production rate of a steroid hormone refers to entry into the blood of the compound from all possible sources, including secretion from glands and conversion of prohormones into the steroid of interest. At steady state, the amount of hormone entering the blood from all sources will be equal to the rate at which it is being cleared (metabolic clearance rate) multiplied by blood concentration (production rate = metabolic clearance rate × concentration). If there is little contribution of prohormone metabolism to the circulating pool of steroid, then the production rate will approximate the secretion rate." Sources: See template.

Distribution edit

Progesterone binds extensively to plasma proteins, including albumin (50–54%) and transcortin (43–48%).[111] It has similar affinity for albumin relative to the PR.[17]

Metabolism edit

The metabolism of progesterone is rapid and extensive and occurs mainly in the liver,[112][113][114] though enzymes that metabolize progesterone are also expressed widely in the brain, skin, and various other extrahepatic tissues.[77][115] Progesterone has an elimination half-life of only approximately 5 minutes in circulation.[112] The metabolism of progesterone is complex, and it may form as many as 35 different unconjugated metabolites when it is ingested orally.[114][116] Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases due to its double bond (between the C4 and C5 positions) and its two ketones (at the C3 and C20 positions).[114]

The major metabolic pathway of progesterone is reduction by 5α-reductase[77] and 5β-reductase into the dihydrogenated 5α-dihydroprogesterone and 5β-dihydroprogesterone, respectively.[113][114][117][118] This is followed by the further reduction of these metabolites via 3α-hydroxysteroid dehydrogenase and 3β-hydroxysteroid dehydrogenase into the tetrahydrogenated allopregnanolone, pregnanolone, isopregnanolone, and epipregnanolone.[119][113][114][117] Subsequently, 20α-hydroxysteroid dehydrogenase and 20β-hydroxysteroid dehydrogenase reduce these metabolites to form the corresponding hexahydrogenated pregnanediols (eight different isomers in total),[113][118] which are then conjugated via glucuronidation and/or sulfation, released from the liver into circulation, and excreted by the kidneys into the urine.[112][114] The major metabolite of progesterone in the urine is the 3α,5β,20α isomer of pregnanediol glucuronide, which has been found to constitute 15 to 30% of an injection of progesterone.[17][120] Other metabolites of progesterone formed by the enzymes in this pathway include 3α-dihydroprogesterone, 3β-dihydroprogesterone, 20α-dihydroprogesterone, and 20β-dihydroprogesterone, as well as various combination products of the enzymes aside from those already mentioned.[17][114][120][121] Progesterone can also first be hydroxylated (see below) and then reduced.[114] Endogenous progesterone is metabolized approximately 50% into 5α-dihydroprogesterone in the corpus luteum, 35% into 3β-dihydroprogesterone in the liver, and 10% into 20α-dihydroprogesterone.[122]

Relatively small portions of progesterone are hydroxylated via 17α-hydroxylase (CYP17A1) and 21-hydroxylase (CYP21A2) into 17α-hydroxyprogesterone and 11-deoxycorticosterone (21-hydroxyprogesterone), respectively,[116] and pregnanetriols are formed secondarily to 17α-hydroxylation.[123][124] Even smaller amounts of progesterone may be also hydroxylated via 11β-hydroxylase (CYP11B1) and to a lesser extent via aldosterone synthase (CYP11B2) into 11β-hydroxyprogesterone.[125][126][44] In addition, progesterone can be hydroxylated in the liver by other cytochrome P450 enzymes which are not steroid-specific.[127] 6β-Hydroxylation, which is catalyzed mainly by CYP3A4, is the major transformation, and is responsible for approximately 70% of cytochrome P450-mediated progesterone metabolism.[127] Other routes include 6α-, 16α-, and 16β-hydroxylation.[114] However, treatment of women with ketoconazole, a strong CYP3A4 inhibitor, had minimal effects on progesterone levels, producing only a slight and non-significant increase, and this suggests that cytochrome P450 enzymes play only a small role in progesterone metabolism.[128]

Metabolism of progesterone in humans[129]
 
This diagram illustrates the metabolic pathways involved in the metabolism of progesterone in humans. In addition to the transformations shown in the diagram, conjugation, specifically glucuronidation and sulfation, occurs with metabolites of progesterone that have one or more available hydroxyl (–OH) groups.

Levels edit

 
Progesterone levels across the menstrual cycle in normally cycling and ovulatory women.[130] The horizontal lines are the mean integrated levels for each curve. The vertical line is mid-cycle.

In women, progesterone levels are relatively low during the preovulatory phase of the menstrual cycle, rise after ovulation, and are elevated during the luteal phase, as shown in the diagram above. Progesterone levels tend to be less than 2 ng/mL prior to ovulation and greater than 5 ng/mL after ovulation. If pregnancy occurs, human chorionic gonadotropin is released, maintaining the corpus luteum and allowing it to maintain levels of progesterone. Between 7 and 9 weeks, the placenta begins to produce progesterone in place of the corpus luteum in a process called the luteal-placental shift.[131]

After the luteal-placental shift, progesterone levels start to rise further and may reach 100 to 200 ng/mL at term. Whether a decrease in progesterone levels is critical for the initiation of labor has been argued and may be species-specific. After delivery of the placenta and during lactation, progesterone levels are very low.

Progesterone levels are low in children and postmenopausal women.[132] Adult males have levels similar to those in women during the follicular phase of the menstrual cycle.

Endogenous progesterone production rates and plasma progesterone levels
Group P4 production P4 levels
Prepubertal children ND 0.06–0.5 ng/mL
Pubertal girls
  Tanner stage I (childhood)
  Tanner stage II (ages 8–12)
  Tanner stage III (ages 10–13)
  Tanner stage IV (ages 11–14)
  Tanner stage V (ages 12–15)
    Follicular phase (days 1–14)
    Luteal phase (days 15–28)		  
ND
ND
ND
ND
 
ND
ND		  
0.22 (<0.10–0.32) ng/mL
0.30 (0.10–0.51) ng/mL
0.36 (0.10–0.75) ng/mL
1.75 (<0.10–25.0) ng/mL
 
0.35 (0.13–0.75) ng/mL
2.0–25.0 ng/mL
Premenopausal women
  Follicular phase (days 1–14)
  Luteal phase (days 15–28)
  Oral contraceptive (anovulatory)		  
0.75–5.4 mg/day
15–50 mg/day
ND		  
0.02–1.2 ng/mL
4–30 ng/mL
0.1–0.3 ng/mL
Postmenopausal women
Oophorectomized women
Oophorectomized and adrenalectomized women		 ND
1.2 mg/day
<0.3 mg/day		 0.03–0.3 ng/mL
0.39 ng/mL
ND
Pregnant women
  First trimester (weeks 1–12)
  Second trimester (weeks 13–26)
  Third trimester (weeks 27–40)
  Postpartum (at 24 hours)		  
55 mg/day
92–100 mg/day
190–563 mg/day
ND		  
9–75 ng/mL
17–146 ng/mL
55–255 ng/mL
19 ng/mL
Men 0.75–3 mg/day 0.1–0.3 ng/mL
Notes: Mean levels are given as a single value and ranges are given after in parentheses. Sources: [129][133][134][135][136][137][138][139][140]

Ranges edit

Blood test results should always be interpreted using the reference ranges provided by the laboratory that performed the results. Example reference ranges are listed below.

Person type Reference range for blood test
Lower limit Upper limit Unit
Female - menstrual cycle (see diagram below)
Female - postmenopausal <0.2[141] 1[141] ng/mL
<0.6[142] 3[142] nmol/L
Female on oral contraceptives 0.34[141] 0.92[141] ng/mL
1.1[142] 2.9[142] nmol/L
Males ≥16 years 0.27[141] 0.9[141] ng/mL
0.86[142] 2.9[142] nmol/L
Female or male 1–9 years 0.1[141] 4.1[141] or 4.5[141] ng/mL
0.3[142] 13[142] nmol/L
Reference ranges for the blood content of progesterone during the menstrual cycle
 
Progesterone levels during the menstrual cycle.[143]
• The ranges denoted By biological stage may be used in closely monitored menstrual cycles in regard to other markers of its biological progression, with the time scale being compressed or stretched to how much faster or slower, respectively, the cycle progresses compared to an average cycle.
• The ranges denoted Inter-cycle variability are more appropriate to use in non-monitored cycles with only the beginning of menstruation known, but where the woman accurately knows her average cycle lengths and time of ovulation, and that they are somewhat averagely regular, with the time scale being compressed or stretched to how much a woman's average cycle length is shorter or longer, respectively, than the average of the population.
• The ranges denoted Inter-woman variability are more appropriate to use when the average cycle lengths and time of ovulation are unknown, but only the beginning of menstruation is given.

Sources edit

Animal edit

Progesterone is produced in high amounts in the ovaries (by the corpus luteum) from the onset of puberty to menopause, and is also produced in smaller amounts by the adrenal glands after the onset of adrenarche in both males and females. To a lesser extent, progesterone is produced in nervous tissue, especially in the brain, and in adipose (fat) tissue, as well.

During human pregnancy, progesterone is produced in increasingly high amounts by the ovaries and placenta. At first, the source is the corpus luteum that has been "rescued" by the presence of human chorionic gonadotropin (hCG) from the conceptus. However, after the 8th week, production of progesterone shifts to the placenta. The placenta utilizes maternal cholesterol as the initial substrate, and most of the produced progesterone enters the maternal circulation, but some is picked up by the fetal circulation and used as substrate for fetal corticosteroids. At term the placenta produces about 250 mg progesterone per day.

An additional animal source of progesterone is milk products. After consumption of milk products the level of bioavailable progesterone goes up.[144]

Plants edit

In at least one plant, Juglans regia, progesterone has been detected.[145] In addition, progesterone-like steroids are found in Dioscorea mexicana. Dioscorea mexicana is a plant that is part of the yam family native to Mexico.[146] It contains a steroid called diosgenin that is taken from the plant and is converted into progesterone.[147] Diosgenin and progesterone are also found in other Dioscorea species, as well as in other plants that are not closely related, such as fenugreek.

Another plant that contains substances readily convertible to progesterone is Dioscorea pseudojaponica native to Taiwan. Research has shown that the Taiwanese yam contains saponins — steroids that can be converted to diosgenin and thence to progesterone.[148]

Many other Dioscorea species of the yam family contain steroidal substances from which progesterone can be produced. Among the more notable of these are Dioscorea villosa and Dioscorea polygonoides. One study showed that the Dioscorea villosa contains 3.5% diosgenin.[149] Dioscorea polygonoides has been found to contain 2.64% diosgenin as shown by gas chromatography-mass spectrometry.[150] Many of the Dioscorea species that originate from the yam family grow in countries that have tropical and subtropical climates.[151]

Medical use edit

Main articles: Progesterone (medication), Pharmacodynamics of progesterone, and Pharmacokinetics of progesterone

Progesterone is used as a medication. It is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women.[116][152] It may also be used alone to treat menopausal symptoms. Studies have shown that transdermal progesterone (skin patch) and oral micronized progesterone are effective treatments for certain symptoms of menopause such as hot flashes and night sweats, which are otherwise referred to as vasomotor symptoms or VMS.[153]

It is also used in women to support pregnancy and fertility and to treat gynecological disorders.[154][155][156][157] Progesterone has been shown to prevent miscarriage in women with 1) vaginal bleeding early in their current pregnancy and 2) a previous history of miscarriage.[158] Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes.[116]

Chemistry edit

 
A sample of progesterone
See also: List of neurosteroids

Progesterone is a naturally occurring pregnane steroid and is also known as pregn-4-ene-3,20-dione.[159][160] It has a double bond (4-ene) between the C4 and C5 positions and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position.[159][160]

Synthesis edit

Progesterone is commercially produced by semisynthesis. Two main routes are used: one from yam diosgenin first pioneered by Marker in 1940, and one based on soy phytosterols scaled up in the 1970s. Additional (not necessarily economical) semisyntheses of progesterone have also been reported starting from a variety of steroids. For the example, cortisone can be simultaneously deoxygenated at the C-17 and C-21 position by treatment with iodotrimethylsilane in chloroform to produce 11-keto-progesterone (ketogestin), which in turn can be reduced at position-11 to yield progesterone.[161]

Marker semisynthesis edit

Main article: Marker degradation

An economical semisynthesis of progesterone from the plant steroid diosgenin isolated from yams was developed by Russell Marker in 1940 for the Parke-Davis pharmaceutical company.[162] This synthesis is known as the Marker degradation.

 
The Marker semisynthesis of progesterone from diosgenin.[162]

The 16-DPA intermediate is important to the synthesis of many other medically important steroids. A very similar approach can produce 16-DPA from solanine.[163]

Soy semisynthesis edit

Progesterone can also be made from the stigmasterol found in soybean oil also. c.f. Percy Julian.

 
Stigmasterol to progesterone synthesis.[164][165][166][167][168]

Total synthesis edit

 
The Johnson total synthesis of progesterone.[169]

A total synthesis of progesterone was reported in 1971 by W.S. Johnson.[169] The synthesis begins with reacting the phosphonium salt 7 with phenyl lithium to produce the phosphonium ylide 8. The ylide 8 is reacted with an aldehyde to produce the alkene 9. The ketal protecting groups of 9 are hydrolyzed to produce the diketone 10, which in turn is cyclized to form the cyclopentenone 11. The ketone of 11 is reacted with methyl lithium to yield the tertiary alcohol 12, which in turn is treated with acid to produce the tertiary cation 13. The key step of the synthesis is the π-cation cyclization of 13 in which the B-, C-, and D-rings of the steroid are simultaneously formed to produce 14. This step resembles the cationic cyclization reaction used in the biosynthesis of steroids and hence is referred to as biomimetic. In the next step the enol orthoester is hydrolyzed to produce the ketone 15. The cyclopentene A-ring is then opened by oxidizing with ozone to produce 16. Finally, the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce progesterone.[169]

History edit

George W. Corner and Willard M. Allen discovered the hormonal action of progesterone in 1929.[17][170][171][172] By 1931–1932, nearly pure crystalline material of high progestational activity had been isolated from the corpus luteum of animals, and by 1934, pure crystalline progesterone had been refined and obtained and the chemical structure of progesterone was determined.[17][171] This was achieved by Adolf Butenandt at the Chemisches Institut of Technical University in Danzig, who extracted this new compound from several thousand liters of urine.[173]

Chemical synthesis of progesterone from stigmasterol and pregnanediol was accomplished later that year.[171][174] Up to this point, progesterone, known generically as corpus luteum hormone, had been being referred to by several groups by different names, including corporin, lutein, luteosterone, and progestin.[17][175] In 1935, at the time of the Second International Conference on the Standardization of Sex Hormones in London, England, a compromise was made between the groups and the name progesterone (progestational steroidal ketone) was created.[17][176]

Veterinary use edit

The use of progesterone tests in dog breeding to pinpoint ovulation is becoming more widely used. There are several tests available but the most reliable test is a blood test with blood drawn by a veterinarian and sent to a lab for processing. Results can usually be obtained with 24 to 72 hours. The rationale for using progesterone tests is that increased numbers begin in close proximity to preovulatory surge in gonadotrophins and continue through ovulation and estrus. When progesterone levels reach certain levels they can signal the stage of estrus the female is. Prediction of birth date of the pending litter can be very accurate if ovulation date is known. Puppies deliver with a day or two of 9 weeks gestation in most cases. It is not possible to determine pregnancy using progesterone tests once a breeding has taken place, however. This is due to the fact that, in dogs, progesterone levels remain elevated throughout the estrus period.[177]

Pricing edit

Pricing for progesterone can vary depending location, insurance coverage, discount coupons, quantity, shortages, manufacturers, brand or generic versions, different pharmacies, and so on. As of currently, 30 capsules of 100 mg of the generic version, Prometrium, from CVS Pharmacy is around $40 without any discounts or insurance applied. The brand version, Progesterone, is around $450 for 30 capsules without any discounts or insurance applied.[178] In comparison, Walgreens offers 30 capsules of 100 mg in the generic version for $51 without insurance or coupons applied. The brand name costs around $431 for 30 capsules of 100 mg.[179]

References edit

  1. ^ a b Jameson JL, De Groot LJ (25 February 2015). Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. p. 2179. ISBN 978-0-323-32195-2.
  2. ^ Adler N, Pfaff D, Goy RW (6 December 2012). Handbook of Behavioral Neurobiology Volume 7 Reproduction (1st ed.). New York: Plenum Press. p. 189. ISBN 978-1-4684-4834-4. Retrieved 4 July 2015.
  3. ^ "progesterone (CHEBI:17026)". ChEBI. European Molecular Biology Laboratory-EBI. Retrieved 4 July 2015.
  4. ^ "Progesterone_msds".
  5. ^ a b Stanczyk FZ (September 2002). "Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception". Reviews in Endocrine & Metabolic Disorders. 3 (3): 211–224. doi:10.1023/A:1020072325818. PMID 12215716. S2CID 27018468.
  6. ^ a b c Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, Hodgen GD (July 1993). "The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone". Fertility and Sterility. 60 (1): 26–33. doi:10.1016/S0015-0282(16)56031-2. PMID 8513955.
  7. ^ Fritz MA, Speroff L (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 44–. ISBN 978-1-4511-4847-3.
  8. ^ Marshall WJ, Bangert SK (2008). Clinical Chemistry. Elsevier Health Sciences. pp. 192–. ISBN 978-0-7234-3455-9.
  9. ^ Yamazaki H, Shimada T (October 1997). "Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes". Archives of Biochemistry and Biophysics. 346 (1): 161–169. doi:10.1006/abbi.1997.0302. PMID 9328296.
  10. ^ McKay GA, Walters MR (6 February 2013). Lecture Notes: Clinical Pharmacology and Therapeutics. John Wiley & Sons. p. 33. ISBN 978-1-118-34489-7.
  11. ^ Zutshi V, Rathore AM, Sharma K (1 January 2005). Hormones in Obstetrics and Gynaecology. Jaypee Brothers Publishers. p. 74. ISBN 978-81-8061-427-9.[permanent dead link]
  12. ^ a b Cometti B (November 2015). "Pharmaceutical and clinical development of a novel progesterone formulation". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 28–37. doi:10.1111/aogs.12765. PMID 26342177. S2CID 31974637.
  13. ^ a b c King TL, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 372–373. ISBN 978-1-4496-5800-7.
  14. ^ a b Baulieu E, Schumacher M (2000). "Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination". Steroids. 65 (10–11): 605–612. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866. S2CID 14952168.
  15. ^ Prior JC (April 2019). "Progesterone Is Important for Transgender Women's Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen". The Journal of Clinical Endocrinology and Metabolism. 104 (4): 1181–1186. doi:10.1210/jc.2018-01777. PMID 30608551. S2CID 58620122. Evidence has accrued that normal progesterone (and ovulation), as well as physiological estradiol levels, is necessary during ciswomen's premenopausal menstrual cycles for current fertility and long-term health; transgender women may require progesterone therapy and similar potential physiological benefits
  16. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 47X. ISBN 9783527607495.
  17. ^ a b c d e f g h Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6.
  18. ^ Thomas P, Pang Y (2012). "Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells". Neuroendocrinology. 96 (2): 162–171. doi:10.1159/000339822. PMC 3489003. PMID 22687885.
  19. ^ Valadez-Cosmes P, Vázquez-Martínez ER, Cerbón M, Camacho-Arroyo I (October 2016). "Membrane progesterone receptors in reproduction and cancer". Molecular and Cellular Endocrinology. 434: 166–175. doi:10.1016/j.mce.2016.06.027. PMID 27368976. S2CID 3826650.
  20. ^ Meyer C, Schmid R, Schmieding K, Falkenstein E, Wehling M (February 1998). "Characterization of high affinity progesterone-binding membrane proteins by anti-peptide antiserum". Steroids. 63 (2): 111–116. doi:10.1016/s0039-128x(97)00143-8. PMID 9516722. S2CID 40096058.
  21. ^ Kabe Y, Handa H, Suematsu M (July 2018). "Function and structural regulation of the carbon monoxide (CO)-responsive membrane protein PGRMC1". Journal of Clinical Biochemistry and Nutrition. 63 (1): 12–17. doi:10.3164/jcbn.17-132. PMC 6064819. PMID 30087538.
  22. ^ Ryu CS, Klein K, Zanger UM (27 March 2017). "Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450". Frontiers in Pharmacology. 8: 159. doi:10.3389/fphar.2017.00159. PMC 5366339. PMID 28396637.
  23. ^ Maurice T, Urani A, Phan VL, Romieu P (November 2001). "The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities". Brain Research. Brain Research Reviews. 37 (1–3): 116–132. doi:10.1016/s0165-0173(01)00112-6. PMID 11744080. S2CID 44931783.
  24. ^ Johannessen M, Fontanilla D, Mavlyutov T, Ruoho AE, Jackson MB (February 2011). "Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels". American Journal of Physiology. Cell Physiology. 300 (2): C328–C337. doi:10.1152/ajpcell.00383.2010. PMC 3043630. PMID 21084640.
  25. ^ a b Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, et al. (October 1993). "Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands". European Journal of Pharmacology. 247 (2): 145–154. doi:10.1016/0922-4106(93)90072-H. PMID 8282004.
  26. ^ Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A (November 2003). "Conception and pharmacodynamic profile of drospirenone". Steroids. 68 (10–13): 891–905. doi:10.1016/j.steroids.2003.08.008. PMID 14667981. S2CID 41756726.
  27. ^ Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN (December 2007). "Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins". American Journal of Obstetrics and Gynecology. 197 (6): 599.e1–599.e7. doi:10.1016/j.ajog.2007.05.024. PMC 2278032. PMID 18060946.
  28. ^ Lei K, Chen L, Georgiou EX, Sooranna SR, Khanjani S, Brosens JJ, et al. (2012). "Progesterone acts via the nuclear glucocorticoid receptor to suppress IL-1β-induced COX-2 expression in human term myometrial cells". PLOS ONE. 7 (11): e50167. Bibcode:2012PLoSO...750167L. doi:10.1371/journal.pone.0050167. PMC 3509141. PMID 23209664.
  29. ^ Paul SM, Purdy RH (March 1992). "Neuroactive steroids". FASEB Journal. 6 (6): 2311–2322. doi:10.1096/fasebj.6.6.1347506. PMID 1347506. S2CID 221753076.
  30. ^ Kliewer SA, Goodwin B, Willson TM (October 2002). "The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism". Endocrine Reviews. 23 (5): 687–702. doi:10.1210/er.2001-0038. PMID 12372848.
  31. ^ Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". The Journal of Clinical Investigation. 102 (5): 1016–1023. doi:10.1172/JCI3703. PMC 508967. PMID 9727070.
  32. ^ Meanwell NA (8 December 2014). Tactics in Contemporary Drug Design. Springer. pp. 161–. ISBN 978-3-642-55041-6.
  33. ^ a b Legato MJ, Bilezikian JP (2004). Principles of Gender-specific Medicine. Gulf Professional Publishing. pp. 146–. ISBN 978-0-12-440906-4.
  34. ^ Williams DA (24 January 2012). "Drug Metabolism". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 164. ISBN 978-1-60913-345-0.
  35. ^ Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 4–. ISBN 978-1-4816-7550-5.
  36. ^ Strünker T, Goodwin N, Brenker C, Kashikar ND, Weyand I, Seifert R, Kaupp UB (March 2011). "The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm". Nature. 471 (7338): 382–386. Bibcode:2011Natur.471..382S. doi:10.1038/nature09769. PMID 21412338. S2CID 4431334.
  37. ^ Lishko PV, Botchkina IL, Kirichok Y (March 2011). "Progesterone activates the principal Ca2+ channel of human sperm". Nature. 471 (7338): 387–391. Bibcode:2011Natur.471..387L. doi:10.1038/nature09767. PMID 21412339. S2CID 4340309.
  38. ^ Prior JC (2020). "Women's reproductive system as balanced estradiol and progesterone actions—A revolutionary, paradigm-shifting concept in women's health". Drug Discovery Today: Disease Models. 32 (Part B): 31–40. doi:10.1016/j.ddmod.2020.11.005.
  39. ^ Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (May 1990). "Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B". The EMBO Journal. 9 (5): 1603–1614. doi:10.1002/j.1460-2075.1990.tb08280.x. PMC 551856. PMID 2328727.
  40. ^ a b Cline JM, Wood CE (1 January 2006). Hallam SZ, Osuch JR (eds.). "Hormonal effects on the mammary gland of postmenopausal nonhuman primates". Breast Disease. IOS Press. 24: 59–70. doi:10.3233/bd-2006-24105. ISBN 978-1-58603-653-9. PMID 16917139.
  41. ^ a b Johnson LR (2003). Essential Medical Physiology. Academic Press. p. 770. ISBN 978-0-12-387584-6.
  42. ^ a b Coad J, Dunstall M (2011). Anatomy and Physiology for Midwives, with Pageburst online access,3: Anatomy and Physiology for Midwives. Elsevier Health Sciences. p. 413. ISBN 978-0-7020-3489-3.
  43. ^ Landau RL, Bergenstal DM, Lugibihl K, Kascht ME (October 1955). "The metabolic effects of progesterone in man". The Journal of Clinical Endocrinology and Metabolism. 15 (10): 1194–1215. doi:10.1210/jcem-15-10-1194. PMID 13263410.
  44. ^ a b c Masiutin M, Yadav M (2023). "Alternative androgen pathways". WikiJournal of Medicine. 10: X. doi:10.15347/WJM/2023.003. S2CID 257943362.
  45. ^ a b O'Shaughnessy PJ, Antignac JP, Le Bizec B, Morvan ML, Svechnikov K, Söder O, et al. (February 2019). "Alternative (backdoor) androgen production and masculinization in the human fetus". PLOS Biology. 17 (2): e3000002. doi:10.1371/journal.pbio.3000002. PMC 6375548. PMID 30763313.
  46. ^ Flück CE, Pandey AV (May 2014). "Steroidogenesis of the testis -- new genes and pathways". Annales d'Endocrinologie. 75 (2): 40–47. doi:10.1016/j.ando.2014.03.002. PMID 24793988.
  47. ^ Zachmann M (February 1996). "Prismatic cases: 17,20-desmolase (17,20-lyase) deficiency". The Journal of Clinical Endocrinology and Metabolism. 81 (2): 457–459. doi:10.1210/jcem.81.2.8636249. PMID 8636249.
  48. ^ Correia JN, Conner SJ, Kirkman-Brown JC (May 2007). "Non-genomic steroid actions in human spermatozoa. "Persistent tickling from a laden environment"". Seminars in Reproductive Medicine. 25 (3): 208–219. doi:10.1055/s-2007-973433. PMID 17447210. S2CID 260318879.
  49. ^ Kirkman-Brown JC, Bray C, Stewart PM, Barratt CL, Publicover SJ (June 2000). "Biphasic elevation of [Ca(2+)](i) in individual human spermatozoa exposed to progesterone". Developmental Biology. 222 (2): 326–335. doi:10.1006/dbio.2000.9729. PMID 10837122.
  50. ^ Kirkman-Brown JC, Barratt CL, Publicover SJ (March 2004). "Slow calcium oscillations in human spermatozoa". The Biochemical Journal. 378 (Pt 3): 827–832. doi:10.1042/BJ20031368. PMC 1223996. PMID 14606954.
  51. ^ Harper CV, Barratt CL, Publicover SJ (October 2004). "Stimulation of human spermatozoa with progesterone gradients to simulate approach to the oocyte. Induction of [Ca(2+)](i) oscillations and cyclical transitions in flagellar beating". The Journal of Biological Chemistry. 279 (44): 46315–46325. doi:10.1074/jbc.M401194200. PMID 15322137.
  52. ^ Marieb E (2013). Anatomy & physiology. Benjamin-Cummings. p. 903. ISBN 9780321887603.
  53. ^ Tosti E, Di Cosmo A, Cuomo A, Di Cristo C, Gragnaniello G (May 2001). "Progesterone induces activation in Octopus vulgaris spermatozoa". Molecular Reproduction and Development. 59 (1): 97–105. doi:10.1002/mrd.1011. PMID 11335951. S2CID 28390608.
  54. ^ a b Bowen R (6 August 2000). "Placental Hormones". Retrieved 12 March 2008.
  55. ^ Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S (2014). "Role of nuclear progesterone receptor isoforms in uterine pathophysiology". Human Reproduction Update. 21 (2): 155–173. doi:10.1093/humupd/dmu056. PMC 4366574. PMID 25406186.
  56. ^ a b Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S (July 2016). "Progesterone in normal and pathological pregnancy". Hormone Molecular Biology and Clinical Investigation. 27 (1): 35–48. doi:10.1515/hmbci-2016-0038. PMID 27662646. S2CID 32239449.
  57. ^ Care A, Nevitt SJ, Medley N, Donegan S, Good L, Hampson L, et al. (February 2022). "Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis". BMJ. 376: e064547. doi:10.1136/bmj-2021-064547. PMC 8845039. PMID 35168930.
  58. ^ Macias H, Hinck L (2012). "Mammary gland development". Wiley Interdisciplinary Reviews. Developmental Biology. 1 (4): 533–557. doi:10.1002/wdev.35. PMC 3404495. PMID 22844349.
  59. ^ a b c Hilton HN, Graham JD, Clarke CL (September 2015). "Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?". Molecular Endocrinology. 29 (9): 1230–1242. doi:10.1210/me.2015-1152. PMC 5414684. PMID 26266959.
  60. ^ Barbieri RL (13 September 2013). "The Breast". In Strauss JF, Barbieri RL (eds.). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 236–. ISBN 978-1-4557-2758-2.
  61. ^ Scaling AL, Prossnitz ER, Hathaway HJ (June 2014). "GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast". Hormones & Cancer. 5 (3): 146–160. doi:10.1007/s12672-014-0174-1. PMC 4091989. PMID 24718936.
  62. ^ a b c d e Aupperlee MD, Leipprandt JR, Bennett JM, Schwartz RC, Haslam SZ (May 2013). "Amphiregulin mediates progesterone-induced mammary ductal development during puberty". Breast Cancer Research. 15 (3): R44. doi:10.1186/bcr3431. PMC 3738150. PMID 23705924.
  63. ^ a b Kuhl H, Schneider HP (August 2013). "Progesterone--promoter or inhibitor of breast cancer". Climacteric. 16 (Suppl 1): 54–68. doi:10.3109/13697137.2013.768806. PMID 23336704. S2CID 20808536.
  64. ^ a b c Trabert B, Sherman ME, Kannan N, Stanczyk FZ (April 2020). "Progesterone and Breast Cancer". Endocrine Reviews. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725.
  65. ^ Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence". Lancet. 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC 6891893. PMID 31474332.
  66. ^ Stute P, Wildt L, Neulen J (April 2018). "The impact of micronized progesterone on breast cancer risk: a systematic review" (PDF). Climacteric. 21 (2): 111–122. doi:10.1080/13697137.2017.1421925. PMID 29384406. S2CID 3642971.
  67. ^ Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ, et al. (July 2016). "Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis". Systematic Reviews. 5 (1): 121. doi:10.1186/s13643-016-0294-5. PMC 4960754. PMID 27456847.
  68. ^ Gompel A, Plu-Bureau G (August 2018). "Progesterone, progestins and the breast in menopause treatment". Climacteric. 21 (4): 326–332. doi:10.1080/13697137.2018.1476483. PMID 29852797. S2CID 46922084.
  69. ^ Davey DA (October 2018). "Menopausal hormone therapy: a better and safer future". Climacteric. 21 (5): 454–461. doi:10.1080/13697137.2018.1439915. PMID 29526116. S2CID 3850275.
  70. ^ a b c d e f g h Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538.
  71. ^ a b c d e f g h Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829.
  72. ^ King SR (9 November 2012). Neurosteroids and the Nervous System. Springer Science & Business Media. pp. 44–46. ISBN 978-1-4614-5559-2.
  73. ^ Fleischman DS, Fessler DM, Cholakians AE (July 2015). "Testing the Affiliation Hypothesis of Homoerotic Motivation in Humans: The Effects of Progesterone and Priming". Archives of Sexual Behavior. 44 (5): 1395–1404. doi:10.1007/s10508-014-0436-6. PMID 25420899. S2CID 9864224.
  74. ^ . UoP News. Archived from the original on 2 July 2019. Retrieved 2 July 2019.
  75. ^ "Having homosexual thoughts 'is an essential part of human evolution' study suggests". The Telegraph. 25 November 2014.
  76. ^ "New Study Identifies Evolutionary Basis Of Homosexuality". HuffPost. 26 November 2014.
  77. ^ a b c Hanukoglu I, Karavolas HJ, Goy RW (April 1977). "Progesterone metabolism in the pineal, brain stem, thalamus and corpus callosum of the female rat". Brain Research. 125 (2): 313–324. doi:10.1016/0006-8993(77)90624-2. PMID 558037. S2CID 35814845.
  78. ^ Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, et al. (June 2004). "Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination". Growth Hormone & IGF Research. 14 (Suppl A): S18–S33. doi:10.1016/j.ghir.2004.03.007. PMID 15135772.
  79. ^ Singh M, Su C, Ng S (September 2013). "Non-genomic mechanisms of progesterone action in the brain". Frontiers in Neuroscience. 7: 159. doi:10.3389/fnins.2013.00159. PMC 3776940. PMID 24065876.
  80. ^ Roof RL, Hall ED (May 2000). "Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone". Journal of Neurotrauma. 17 (5): 367–388. doi:10.1089/neu.2000.17.367. PMID 10833057.
  81. ^ Pan DS, Liu WG, Yang XF, Cao F (October 2007). "Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury". Biomedical and Environmental Sciences. 20 (5): 432–438. PMID 18188998.
  82. ^ Jiang C, Zuo F, Wang Y, Wan J, Yang Z, Lu H, et al. (June 2016). "Progesterone exerts neuroprotective effects and improves long-term neurologic outcome after intracerebral hemorrhage in middle-aged mice". Neurobiology of Aging. 42: 13–24. doi:10.1016/j.neurobiolaging.2016.02.029. PMC 4857017. PMID 27143417.
  83. ^ a b Luoma JI, Stern CM, Mermelstein PG (August 2012). "Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated neuroprotection". The Journal of Steroid Biochemistry and Molecular Biology. 131 (1–2): 30–36. doi:10.1016/j.jsbmb.2011.11.002. PMC 3303940. PMID 22101209.
  84. ^ a b c Stein DG (March 2008). "Progesterone exerts neuroprotective effects after brain injury". Brain Research Reviews. 57 (2): 386–397. doi:10.1016/j.brainresrev.2007.06.012. PMC 2699575. PMID 17826842.
  85. ^ Espinoza TR, Wright DW (2011). "The role of progesterone in traumatic brain injury". The Journal of Head Trauma Rehabilitation. 26 (6): 497–499. doi:10.1097/HTR.0b013e31823088fa. PMC 6025750. PMID 22088981.
  86. ^ Jiang C, Zuo F, Wang Y, Lu H, Yang Q, Wang J (January 2016). "Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke". Molecular Neurobiology. 54 (1): 571–581. doi:10.1007/s12035-015-9651-y. PMC 4938789. PMID 26746666.
  87. ^ Herson PS, Koerner IP, Hurn PD (May 2009). "Sex, sex steroids, and brain injury". Seminars in Reproductive Medicine. 27 (3): 229–239. doi:10.1055/s-0029-1216276. PMC 2675922. PMID 19401954.
  88. ^ Li Z, Wang B, Kan Z, Zhang B, Yang Z, Chen J, et al. (January 2012). "Progesterone increases circulating endothelial progenitor cells and induces neural regeneration after traumatic brain injury in aged rats". Journal of Neurotrauma. 29 (2): 343–353. doi:10.1089/neu.2011.1807. PMC 3261789. PMID 21534727.
  89. ^ a b Lynch WJ, Sofuoglu M (December 2010). "Role of progesterone in nicotine addiction: evidence from initiation to relapse". Experimental and Clinical Psychopharmacology. 18 (6): 451–461. doi:10.1037/a0021265. PMC 3638762. PMID 21186920.
  90. ^ Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CM, et al. (April 2012). "Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers". Archives of General Psychiatry. 69 (4): 418–427. doi:10.1001/archgenpsychiatry.2011.1465. PMC 3508698. PMID 22474108.
  91. ^ Mello NK, Knudson IM, Kelly M, Fivel PA, Mendelson JH (October 2011). "Effects of progesterone and testosterone on cocaine self-administration and cocaine discrimination by female rhesus monkeys". Neuropsychopharmacology. 36 (11): 2187–2199. doi:10.1038/npp.2011.130. PMC 3176575. PMID 21796112.
  92. ^ Buser T (1 June 2012). "The impact of the menstrual cycle and hormonal contraceptives on competitiveness" (PDF). Journal of Economic Behavior & Organization. Gender Differences in Risk Aversion and Competition. 83 (1): 1–10. doi:10.1016/j.jebo.2011.06.006. ISSN 0167-2681.
  93. ^ Sriram D (2007). Medicinal Chemistry. New Delhi: Dorling Kindersley India Pvt. Ltd. p. 432. ISBN 978-81-317-0031-0.
  94. ^ a b Blackburn S (14 April 2014). Maternal, Fetal, & Neonatal Physiology. Elsevier Health Sciences. pp. 92–. ISBN 978-0-323-29296-2.
  95. ^ Faivre EJ, Lange CA (January 2007). "Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells". Molecular and Cellular Biology. 27 (2): 466–480. doi:10.1128/MCB.01539-06. PMC 1800800. PMID 17074804.
  96. ^ Nosek TM. . Essentials of Human Physiology. Archived from the original on 24 March 2016.
  97. ^ Rothchild I (1969), Salhanick HA, Kipnis DM, Wiele RL (eds.), "The Physiologic Basis for the Temperature Raising Effect of Progesterone", Metabolic Effects of Gonadal Hormones and Contraceptive Steroids, Boston, MA: Springer US, pp. 668–675, doi:10.1007/978-1-4684-1782-1_49, ISBN 978-1-4684-1782-1, retrieved 22 March 2021
  98. ^ Hould FS, Fried GM, Fazekas AG, Tremblay S, Mersereau WA (December 1988). "Progesterone receptors regulate gallbladder motility". The Journal of Surgical Research. 45 (6): 505–512. doi:10.1016/0022-4804(88)90137-0. PMID 3184927.
  99. ^ "Hormones and Oral Health". WebMD.
  100. ^ Picard F, Wanatabe M, Schoonjans K, Lydon J, O'Malley BW, Auwerx J (November 2002). "Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferation". Proceedings of the National Academy of Sciences of the United States of America. 99 (24): 15644–15648. doi:10.1073/pnas.202612199. PMC 137770. PMID 12438645.
  101. ^ Brănişteanu DD, Mathieu C (March 2003). "Progesterone in gestational diabetes mellitus: guilty or not guilty?". Trends in Endocrinology and Metabolism. 14 (2): 54–56. doi:10.1016/S1043-2760(03)00003-1. PMID 12591170. S2CID 38209977.
  102. ^ Whynott RM, Summers KM, Jakubiak M, Van Voorhis BJ, Mejia RB (June 2021). "The effect of weight and body mass index on serum progesterone values and live birth rate in cryopreserved in vitro fertilization cycles". F&S Reports. 2 (2): 195–200. doi:10.1016/j.xfre.2021.02.005. PMC 8267385. PMID 34278354.
  103. ^ Kaemmle LM, Stadler A, Janka H, von Wolff M, Stute P (August 2022). "The impact of micronized progesterone on cardiovascular events - a systematic review". Climacteric. 25 (4): 327–336. doi:10.1080/13697137.2021.2022644. PMID 35112635. S2CID 246487187.
  104. ^ Gasser S, Heidemeyer K, von Wolff M, Stute P (June 2021). "Impact of progesterone on skin and hair in menopause - a comprehensive review". Climacteric. 24 (3): 229–235. doi:10.1080/13697137.2020.1838476. PMID 33527841. S2CID 231757325.
  105. ^ Javed AA, Mayhew AJ, Shea AK, Raina P (August 2019). "Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis". JAMA Network Open. 2 (8): e1910154. doi:10.1001/jamanetworkopen.2019.10154. PMC 6716293. PMID 31461147.
  106. ^ Coquoz A, Gruetter C, Stute P (April 2019). "Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review". Climacteric. 22 (2): 148–161. doi:10.1080/13697137.2018.1514003. PMID 30477366. S2CID 53782622.
  107. ^ Häggström M, Richfield D (2014). "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.005. ISSN 2002-4436.
  108. ^ Bewick PM (2002). Medicinal natural products: a biosynthetic approach. New York: Wiley. p. 244. ISBN 0-471-49641-3.
  109. ^ Duport C, Spagnoli R, Degryse E, Pompon D (February 1998). "Self-sufficient biosynthesis of pregnenolone and progesterone in engineered yeast". Nature Biotechnology. 16 (2): 186–189. doi:10.1038/nbt0298-186. PMID 9487528. S2CID 852617.
  110. ^ Zavod RM (24 January 2012). "Women's Health". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1397–. ISBN 978-1-60913-345-0.
  111. ^ Progesterone - Drugs.com, retrieved 23 August 2015
  112. ^ a b c Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 22–. ISBN 978-0-323-03309-1.
  113. ^ a b c d Cupps PT (20 February 1991). Reproduction in Domestic Animals. Elsevier. pp. 101–. ISBN 978-0-08-057109-6.
  114. ^ a b c d e f g h i Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264.
  115. ^ Dowd FJ, Johnson B, Mariotti A (3 September 2016). Pharmacology and Therapeutics for Dentistry. Elsevier Health Sciences. pp. 448–. ISBN 978-0-323-44595-5.
  116. ^ a b c d Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  117. ^ a b Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction. Academic Press. pp. 304–. ISBN 978-0-12-397769-4.
  118. ^ a b Santoro NF, Neal-Perry G (11 September 2010). Amenorrhea: A Case-Based, Clinical Guide. Springer Science & Business Media. pp. 13–. ISBN 978-1-60327-864-5.
  119. ^ Reddy DS (2010). "Neurosteroids". Sex Differences in the Human Brain, their Underpinnings and Implications. Progress in Brain Research. Vol. 186. Elsevier. pp. 113–37. doi:10.1016/B978-0-444-53630-3.00008-7. ISBN 9780444536303. PMC 3139029. PMID 21094889.
  120. ^ a b Baulieu E, Kelly PA (30 November 1990). Hormones: From Molecules to Disease. Springer Science & Business Media. pp. 401–. ISBN 978-0-412-02791-8.
  121. ^ Beranič N, Gobec S, Rižner TL (May 2011). "Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3". Chemico-Biological Interactions. 191 (1–3): 227–233. Bibcode:2011CBI...191..227B. doi:10.1016/j.cbi.2010.12.012. PMID 21182831.
  122. ^ Anderson GD, Odegard PS (October 2004). "Pharmacokinetics of estrogen and progesterone in chronic kidney disease". Advances in Chronic Kidney Disease. 11 (4): 357–360. doi:10.1053/j.ackd.2004.07.001. PMID 15492972.
  123. ^ Greenblatt JM, Brogan K (27 April 2016). Integrative Therapies for Depression: Redefining Models for Assessment, Treatment and Prevention. CRC Press. pp. 201–. ISBN 978-1-4987-0230-0.
  124. ^ Graham C (2 December 2012). Reproductive Biology of the Great Apes: Comparative and Biomedical Perspectives. Elsevier. pp. 179–. ISBN 978-0-323-14971-6.
  125. ^ Strushkevich N, Gilep AA, Shen L, Arrowsmith CH, Edwards AM, Usanov SA, Park HW (February 2013). "Structural insights into aldosterone synthase substrate specificity and targeted inhibition". Molecular Endocrinology. 27 (2): 315–324. doi:10.1210/me.2012-1287. PMC 5417327. PMID 23322723.
  126. ^ van Rooyen D, Gent R, Barnard L, Swart AC (April 2018). "The in vitro metabolism of 11β-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway". The Journal of Steroid Biochemistry and Molecular Biology. 178: 203–212. doi:10.1016/j.jsbmb.2017.12.014. PMID 29277707. S2CID 3700135.
  127. ^ a b de Azevedo Piccinato C (2008). Regulation of Steroid Metabolism and the Hepatic Transcriptome by Estradiol and Progesterone. pp. 24–25. ISBN 978-1-109-04632-8.[permanent dead link]
  128. ^ Akalin S (January 1991). "Effects of ketoconazole in hirsute women". Acta Endocrinologica. 124 (1): 19–22. doi:10.1530/acta.0.1240019. PMID 1825737. S2CID 9831739.
  129. ^ a b Aufrère MB, Benson H (June 1976). "Progesterone: an overview and recent advances". Journal of Pharmaceutical Sciences. 65 (6): 783–800. doi:10.1002/jps.2600650602. PMID 945344.
  130. ^ Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R (2006). "Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer". Clinical Chemistry and Laboratory Medicine. 44 (7): 883–887. doi:10.1515/CCLM.2006.160. PMID 16776638. S2CID 524952.
  131. ^ Csapo AI, Pulkkinen MO, Wiest WG (March 1973). "Effects of luteectomy and progesterone replacement therapy in early pregnant patients". American Journal of Obstetrics and Gynecology. 115 (6): 759–765. doi:10.1016/0002-9378(73)90517-6. PMID 4688578.
  132. ^ NIH Clinical Center (16 August 2004). . United States National Institutes of Health. Archived from the original on 9 January 2009. Retrieved 12 March 2008.
  133. ^ Chernecky CC, Berger BJ (31 October 2012). Laboratory Tests and Diagnostic Procedures - E-Book. Elsevier Health Sciences. pp. 908–. ISBN 978-1-4557-4502-9.
  134. ^ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 889, 940. ISBN 978-0-7817-1750-2.
  135. ^ Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29, 139. ISBN 978-1-4613-2157-6.
  136. ^ van Keep P, Utian W (6 December 2012). The Premenstrual Syndrome: Proceedings of a workshop held during the Sixth International Congress of Psychosomatic Obstetrics and Gynecology, Berlin, September 1980. Springer Science & Business Media. pp. 51–52. ISBN 978-94-011-6255-5.
  137. ^ Strauss JF, Barbieri RL (2009). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. pp. 807–. ISBN 978-1-4160-4907-4.
  138. ^ Bajaj L, Berman S (1 January 2011). Berman's Pediatric Decision Making. Elsevier Health Sciences. pp. 160–. ISBN 978-0-323-05405-8.
  139. ^ Lauritzen C (1988). "Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien" [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles]. In Hermann P. G. Schneider, Christian Lauritzen, Eberhard Nieschlag (eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (in German). Walter de Gruyter. pp. 229–306. ISBN 978-3110109689. OCLC 35483492.
  140. ^ Little, A. B., & Billiar, R. B. (1983). Progestagens. In Endocrinology of Pregnancy, 3rd Edition (pp. 92–111). Harper and Row Philadelphia. https://scholar.google.com/scholar?cluster=2512291948467467634
  141. ^ a b c d e f g h i , Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09
  142. ^ a b c d e f g h Converted from mass values using molar mass of 314.46 g/mol
  143. ^ Häggström M (2014). "Reference ranges for estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle". WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.001. ISSN 2002-4436. S2CID 88035135.
  144. ^ Goodson III WH, Handagama P, Moore II DH, Dairkee S (13 December 2007). "Milk products are a source of dietary progesterone". 30th Annual San Antonio Breast Cancer Symposium. pp. abstract # 2028. Retrieved 12 March 2008.
  145. ^ Pauli GF, Friesen JB, Gödecke T, Farnsworth NR, Glodny B (March 2010). "Occurrence of progesterone and related animal steroids in two higher plants". Journal of Natural Products. 73 (3): 338–345. doi:10.1021/np9007415. PMID 20108949. S2CID 26467578.
  146. ^ Applezweig N (May 1969). "Steroids". Chemical Week. 104: 57–72. PMID 12255132.
  147. ^ Noguchi E, Fujiwara Y, Matsushita S, Ikeda T, Ono M, Nohara T (September 2006). "Metabolism of tomato steroidal glycosides in humans". Chemical & Pharmaceutical Bulletin. 54 (9): 1312–1314. doi:10.1248/cpb.54.1312. PMID 16946542.
  148. ^ Yang DJ, Lu TJ, Hwang LS (October 2003). "Isolation and identification of steroidal saponins in Taiwanese yam cultivar (Dioscorea pseudojaponica Yamamoto)" (PDF). Journal of Agricultural and Food Chemistry. 51 (22): 6438–6444. doi:10.1021/jf030390j. PMID 14558759.
  149. ^ "Final report of the amended safety assessment of Dioscorea Villosa (Wild Yam) root extract". International Journal of Toxicology. 23 (Suppl 2): 49–54. 2004. doi:10.1080/10915810490499055. PMID 15513824. S2CID 962216.
  150. ^ Niño J, Jiménez DA, Mosquera OM, Correa YM (2007). "Diosgenin quantification by HPLC in a Dioscorea polygonoides tuber collection from colombian flora". Journal of the Brazilian Chemical Society. 18 (5): 1073–1076. doi:10.1590/S0103-50532007000500030. S2CID 95193700.
  151. ^ Myoda T, Nagai T, Nagashima T (2005). "Properties of starches in yam (Dioscorea spp.) tuber". Current Topics in Food Science and Technology: 105–114. ISBN 81-308-0003-9.
  152. ^ Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.
  153. ^ Dolitsky SN, Cordeiro Mitchell CN, Stadler SS, Segars JH (November 2020). "Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review". Menopause. 28 (2): 217–224. doi:10.1097/GME.0000000000001676. PMID 33109992. S2CID 225100434.
  154. ^ Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–255. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
  155. ^ Filicori M (November 2015). "Clinical roles and applications of progesterone in reproductive medicine: an overview". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 3–7. doi:10.1111/aogs.12791. PMID 26443945.
  156. ^ Ciampaglia W, Cognigni GE (November 2015). "Clinical use of progesterone in infertility and assisted reproduction". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 17–27. doi:10.1111/aogs.12770. PMID 26345161. S2CID 40753277.
  157. ^ Choi SJ (September 2017). "Use of progesterone supplement therapy for prevention of preterm birth: review of literatures". Obstetrics & Gynecology Science. 60 (5): 405–420. doi:10.5468/ogs.2017.60.5.405. PMC 5621069. PMID 28989916.
  158. ^ Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. (June 2020). "Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT". Health Technology Assessment. 24 (33): 1–70. doi:10.3310/hta24330. PMC 7355406. PMID 32609084.
  159. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1024–. ISBN 978-1-4757-2085-3.
  160. ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 880–. ISBN 978-3-88763-075-1.
  161. ^ Numazawa M, Nagaoka M, Kunitama Y (September 1986). "Regiospecific deoxygenation of the dihydroxyacetone moiety at C-17 of corticoid steroids with iodotrimethylsilane". Chemical & Pharmaceutical Bulletin. 34 (9): 3722–3726. doi:10.1248/cpb.34.3722. PMID 3815593.
  162. ^ a b Marker RE, Krueger J (1940). "Sterols. CXII. Sapogenins. XLI. The Preparation of Trillin and its Conversion to Progesterone". J. Am. Chem. Soc. 62 (12): 3349–3350. doi:10.1021/ja01869a023.
  163. ^ Goswami A, Kotoky R, Rastogi RC, Ghosh AC (1 May 2003). "A One-Pot Efficient Process for 16-Dehydropregnenolone Acetate". Organic Process Research & Development. 7 (3): 306–308. doi:10.1021/op0200625.
  164. ^ Heyl FW (1950). "Progesterone from 3-Acetoxybisnor-5-cholenaldehyde and 3-Ketobisnor-4-cholenaldehyde". Journal of the American Chemical Society. 72 (6): 2617–2619. doi:10.1021/ja01162a076.
  165. ^ Slomp G (1958). "Ozonolysis. II. 1 The Effect of Pyridine on the Ozonolysis of 4,22-Stigmastadien-3-one 2". Journal of the American Chemical Society. 80 (4): 915–921. doi:10.1021/ja01537a041.
  166. ^ Sundararaman P, Djerassi C (October 1977). "A convenient synthesis of progesterone from stigmasterol". The Journal of Organic Chemistry. 42 (22): 3633–3634. doi:10.1021/jo00442a044. PMID 915584.
  167. ^ "Nova Transcripts: Forgotten Genius". PBS.org. 6 February 2007.
  168. ^ . lipidlibrary.aocs.org. Archived from the original on 15 April 2012.
  169. ^ a b c Johnson WS, Gravestock MB, McCarry BE (August 1971). "Acetylenic bond participation in biogenetic-like olefinic cyclizations. II. Synthesis of dl-progesterone". Journal of the American Chemical Society. 93 (17): 4332–4334. doi:10.1021/ja00746a062. PMID 5131151.
  170. ^ Corner GW, Allen WM (1 March 1929). "Physiology of the corpus luteum". American Journal of Physiology. Legacy Content. 88 (2): 326–339. doi:10.1152/ajplegacy.1929.88.2.326. ISSN 0002-9513.
  171. ^ a b c Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford University Press. pp. 31–. ISBN 978-0-19-513021-8.
  172. ^ Walker A (7 March 2008). The Menstrual Cycle. Routledge. pp. 49–. ISBN 978-1-134-71411-7.
  173. ^ Piosik R (2003). "Adolf Butenandt und sein Wirken an der Technischen Hochschule Danzig". Chemkon. 10 (3): 135–138. doi:10.1002/ckon.200390038.
  174. ^ Ginsburg B (6 December 2012). Premenstrual Syndrome: Ethical and Legal Implications in a Biomedical Perspective. Springer Science & Business Media. pp. 274–. ISBN 978-1-4684-5275-4.
  175. ^ Rolleston HD (1936). The Endocrine Organs in Health and Disease: With an Historical Review. Oxford University Press, H. Milford. p. 406.
  176. ^ Allen WM (October 1970). "Progesterone: how did the name originate?". Southern Medical Journal. 63 (10): 1151–1155. doi:10.1097/00007611-197010000-00012. PMID 4922128. S2CID 35867375.
  177. ^ Refsal K (February 2009). "Interpretation of Serum Progesterone Results for Management of Breeding in Dogs" (PDF). Webcd.endo.ref.
  178. ^ "Progesterone Prices, Coupons & Savings Tips - GoodRx". www.goodrx.com. Retrieved 1 August 2023.
  179. ^ "Progesterone Prices, Coupons & Savings Tips - GoodRx". www.goodrx.com. Retrieved 1 August 2023.

External links edit

  • Progesterone MS Spectrum
  • Progesterone at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  • Kimball JW (27 May 2007). . Kimball's Biology Pages. Archived from the original on 18 June 2008. Retrieved 18 June 2008.

February 16, 2024
progesterone, this, article, about, progesterone, hormone, medication, progesterone, medication, endogenous, steroid, progestogen, hormone, involved, menstrual, cycle, pregnancy, embryogenesis, humans, other, species, belongs, group, steroid, hormones, called,. This article is about progesterone as a hormone For its use as a medication see progesterone medication Progesterone P4 is an endogenous steroid and progestogen sex hormone involved in the menstrual cycle pregnancy and embryogenesis of humans and other species 1 13 It belongs to a group of steroid hormones called the progestogens 13 and is the major progestogen in the body Progesterone has a variety of important functions in the body It is also a crucial metabolic intermediate in the production of other endogenous steroids including the sex hormones and the corticosteroids and plays an important role in brain function as a neurosteroid 14 Progesterone NamesIUPAC name Pregn 4 ene 3 20 dione 2 3 Systematic IUPAC name 1S 3aS 3bS 9aR 9bS 11aS 1 Acetyl 9a 11a dimethyl 1 2 3 3a 3b 4 5 8 9 9a 9b 10 11 11a tetradecahydro 7H cyclopenta a phenanthren 7 oneOther names P4 1 PregnenedioneIdentifiersCAS Number 57 83 0 Y3D model JSmol Interactive imageChEBI CHEBI 17026 YChEMBL ChEMBL103 YChemSpider 5773 YDrugBank DB00396 YECHA InfoCard 100 000 318KEGG C00410 NPubChem CID 5994UNII 4G7DS2Q64Y YCompTox Dashboard EPA DTXSID3022370InChI InChI 1S C21H30O2 c1 13 22 17 6 7 18 16 5 4 14 12 15 23 8 10 20 14 2 19 16 9 11 21 17 18 3 h12 16 19H 4 11H2 1 3H3 t16 17 18 19 20 21 m0 s1 NKey RJKFOVLPORLFTN LEKSSAKUSA N YSMILES CC O C H 1CC C H 2 C 1 CC C H 3 C H 2CCC4 CC O CC C 34C CPropertiesChemical formula C 21H 30O 2Molar mass 314 469 g molMelting point 126log P 4 04 4 PharmacologyATC code G03DA04 WHO Routes ofadministration By mouth topical transdermal vaginal intramuscular injection subcutaneous injection subcutaneous implantPharmacokinetics Bioavailability OMP lt 10 5 6 Protein binding Albumin 80 CBG 18 SHBG lt 1 Free 1 2 7 8 Metabolism Hepatic CYP2C19 CYP3A4 CYP2C9 5a reductase 3a HSDTooltip 3a hydroxysteroid dehydrogenase 17a hydroxylase 21 hydroxylase 20a HSDTooltip 20a hydroxysteroid dehydrogenase 9 10 Biological half life OMP 16 18 hours 5 6 11 IM 22 26 hours 6 12 SC 13 18 hours 12 Excretion RenalExcept where otherwise noted data are given for materials in their standard state at 25 C 77 F 100 kPa N verify what is Y N Infobox references In addition to its role as a natural hormone progesterone is also used as a medication such as in combination with estrogen for contraception to reduce the risk of uterine or cervical cancer in hormone replacement therapy and in feminizing hormone therapy 15 It was first prescribed in 1934 16 Contents 1 Biological activity 2 Biological function 2 1 Hormonal interactions 2 2 Early sexual differentiation 2 3 Reproductive system 2 4 Breasts 2 4 1 Lobuloalveolar development 2 4 2 Ductal development 2 4 3 Breast cancer risk 2 5 Skin health 2 6 Sexuality 2 6 1 Libido 2 6 2 Homosexuality 2 7 Nervous system 2 8 Brain damage 2 8 1 Proposed mechanism 2 9 Addiction 2 10 Societal 2 11 Other effects 3 Biochemistry 3 1 Biosynthesis 3 2 Distribution 3 3 Metabolism 3 4 Levels 3 4 1 Ranges 3 5 Sources 3 5 1 Animal 3 5 2 Plants 4 Medical use 5 Chemistry 5 1 Synthesis 5 1 1 Marker semisynthesis 5 1 2 Soy semisynthesis 5 1 3 Total synthesis 6 History 6 1 Veterinary use 6 2 Pricing 7 References 8 External linksBiological activity editSee also Pharmacodynamics of progesterone Mechanism of action Progesterone is the most important progestogen in the body As a potent agonist of the nuclear progesterone receptor nPR with an affinity of KD 1 nM the resulting effects on ribosomal transcription plays a major role in regulation of female reproduction 13 17 In addition progesterone is an agonist of the more recently discovered membrane progesterone receptors mPRs 18 of which the expression has regulation effects in reproduction function oocyte maturation labor and sperm motility and cancer although additional research is required to further define the roles 19 It also functions as a ligand of the PGRMC1 progesterone receptor membrane component 1 which impacts tumor progression metabolic regulation and viability control of nerve cells 20 21 22 Moreover progesterone is also known to be an antagonist of the sigma s1 receptor 23 24 a negative allosteric modulator of nicotinic acetylcholine receptors 14 and a potent antagonist of the mineralocorticoid receptor MR 25 Progesterone prevents MR activation by binding to this receptor with an affinity exceeding even those of aldosterone and glucocorticoids such as cortisol and corticosterone 25 and produces antimineralocorticoid effects such as natriuresis at physiological concentrations 26 In addition progesterone binds to and behaves as a partial agonist of the glucocorticoid receptor GR albeit with very low potency EC50 gt 100 fold less relative to cortisol 27 28 Progesterone through its neurosteroid active metabolites such as 5a dihydroprogesterone and allopregnanolone acts indirectly as a positive allosteric modulator of the GABAA receptor 29 Progesterone and some of its metabolites such as 5b dihydroprogesterone are agonists of the pregnane X receptor PXR 30 albeit weakly so EC50 gt 10 mM 31 In accordance progesterone induces several hepatic cytochrome P450 enzymes 32 such as CYP3A4 33 34 especially during pregnancy when concentrations are much higher than usual 35 Perimenopausal women have been found to have greater CYP3A4 activity relative to men and postmenopausal women and it has been inferred that this may be due to the higher progesterone levels present in perimenopausal women 33 Progesterone modulates the activity of CatSper cation channels of sperm voltage gated Ca2 channels Since eggs release progesterone sperm may use progesterone as a homing signal to swim toward eggs chemotaxis As a result it has been suggested that substances that block the progesterone binding site on CatSper channels could potentially be used in male contraception 36 37 Biological function edit nbsp During the menstrual cycle levels of estradiol an estrogen vary by 200 percent Levels of progesterone vary by over 1200 percent 38 Hormonal interactions edit Progesterone has a number of physiological effects that are amplified in the presence of estrogens Estrogens through estrogen receptors ERs induce or upregulate the expression of the PR 39 One example of this is in breast tissue where estrogens allow progesterone to mediate lobuloalveolar development 40 41 42 Elevated levels of progesterone potently reduce the sodium retaining activity of aldosterone resulting in natriuresis and a reduction in extracellular fluid volume Progesterone withdrawal on the other hand is associated with a temporary increase in sodium retention reduced natriuresis with an increase in extracellular fluid volume due to the compensatory increase in aldosterone production which combats the blockade of the mineralocorticoid receptor by the previously elevated level of progesterone 43 Early sexual differentiation edit Progesterone plays a role in early human sexual differentiation 44 Placental progesterone is the feedstock for the 5a dihydrotestosterone DHT produced via the backdoor pathway found operating in multiple non gonadal tissues of the fetus 45 whereas deficiencies in this pathway lead to undervirilization of the male fetus resulting in incomplete development of the male genitalia 46 47 DHT is a potent androgen that is responsible for the development of male genitalia including the penis and scrotum During early fetal development the undifferentiated gonads can develop into either testes or ovaries The presence of the Y chromosome leads to the development of testes The testes then produce testosterone which is converted to DHT via the enzyme 5a reductase DHT is a potent androgen that is responsible for the masculinization of the external genitalia and the development of the prostate gland Progesterone produced by the placenta during pregnancy plays a role in fetal sexual differentiation by serving as a precursor molecule for the synthesis of DHT via the backdoor pathway In the absence of adequate levels of steroidogenic enzymes during fetal development the backdoor pathway for DHT synthesis can become deficient leading to undermasculinization of the male fetus This can result in the development of ambiguous genitalia or even female genitalia in some cases Therefore both DHT and progesterone play crucial roles in early fetal sexual differentiation with progesterone acting as a precursor molecule for DHT synthesis and DHT promoting the development of male genitalia 44 Reproductive system edit nbsp Micrograph showing changes to the endometrium due to progesterone decidualization H amp E stain Progesterone has key effects via non genomic signalling on human sperm as they migrate through the female tract before fertilization occurs though the receptor s as yet remain unidentified 48 Detailed characterisation of the events occurring in sperm in response to progesterone has elucidated certain events including intracellular calcium transients and maintained changes 49 slow calcium oscillations 50 now thought to possibly regulate motility 51 It is produced by the ovaries 52 Progesterone has also been shown to demonstrate effects on octopus spermatozoa 53 Progesterone is sometimes called the hormone of pregnancy 54 and it has many roles relating to the development of the fetus Progesterone converts the endometrium to its secretory stage to prepare the uterus for implantation At the same time progesterone affects the vaginal epithelium and cervical mucus making it thick and impenetrable to sperm Progesterone is anti mitogenic in endometrial epithelial cells and as such mitigates the tropic effects of estrogen 55 If pregnancy does not occur progesterone levels will decrease leading to menstruation Normal menstrual bleeding is progesterone withdrawal bleeding If ovulation does not occur and the corpus luteum does not develop levels of progesterone may be low leading to anovulatory dysfunctional uterine bleeding During implantation and gestation progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy 56 Progesterone decreases contractility of the uterine smooth muscle 54 This effect contributes to prevention of preterm labor 56 Studies have shown that in women who are pregnant with a single fetus asymptomatic in the prenatal stage and at a high risk of giving pre term birth spontaneously vaginal progesterone medication has been found to be effective in preventing spontaneous pre term birth Women who are at a high risk of giving pre term birth spontaneously are those who have a short cervix of less than 25 mm or have previously given pre term birth spontaneously Although pre term births are generally considered to be less than 37 weeks these studies found that vaginal progesterone is associated with fewer pre term births of less than 34 weeks 57 A drop in progesterone levels is possibly one step that facilitates the onset of labor In addition progesterone inhibits lactation during pregnancy The fall in progesterone levels following delivery is one of the triggers for milk production The fetus metabolizes placental progesterone in the production of adrenal steroids 45 Breasts edit See also Breast development Biochemistry Lobuloalveolar development edit Progesterone plays an important role in breast development in women In conjunction with prolactin it mediates lobuloalveolar maturation of the mammary glands during pregnancy to allow for milk production and thus lactation and breastfeeding of offspring following parturition childbirth 58 Estrogen induces expression of the PR in breast tissue and hence progesterone is dependent on estrogen to mediate lobuloalveolar development 40 41 42 It has been found that RANKLTooltip Receptor activator of nuclear factor kappa B ligand is a critical downstream mediator of progesterone induced lobuloalveolar maturation 59 RANKL knockout mice show an almost identical mammary phenotype to PR knockout mice including normal mammary ductal development but complete failure of the development of lobuloalveolar structures 59 Ductal development edit Though to a far lesser extent than estrogen which is the major mediator of mammary ductal development via the ERa 60 61 progesterone may be involved in ductal development of the mammary glands to some extent as well 62 PR knockout mice or mice treated with the PR antagonist mifepristone show delayed although otherwise normal mammary ductal development at puberty 62 In addition mice modified to have overexpression of PRA display ductal hyperplasia 59 and progesterone induces ductal growth in the mouse mammary gland 62 Progesterone mediates ductal development mainly via induction of the expression of amphiregulin the same growth factor that estrogen primarily induces the expression of to mediate ductal development 62 These animal findings suggest that while not essential for full mammary ductal development progesterone seems to play a potentiating or accelerating role in estrogen mediated mammary ductal development 62 Breast cancer risk edit Progesterone also appears to be involved in the pathophysiology of breast cancer though its role and whether it is a promoter or inhibitor of breast cancer risk has not been fully elucidated 63 64 Most progestins or synthetic progestogens like medroxyprogesterone acetate have been found to increase the risk of breast cancer in postmenopausal women in combination with estrogen as a component of menopausal hormone therapy 65 64 The combination of natural oral progesterone or the atypical progestin dydrogesterone with estrogen has been associated with less risk of breast cancer than progestins plus estrogen 66 67 68 However this may simply be an artifact of the low progesterone levels produced with oral progesterone 63 69 More research is needed on the role of progesterone in breast cancer 64 Skin health edit The estrogen receptor as well as the progesterone receptor have been detected in the skin including in keratinocytes and fibroblasts 70 71 At menopause and thereafter decreased levels of female sex hormones result in atrophy thinning and increased wrinkling of the skin and a reduction in skin elasticity firmness and strength 70 71 These skin changes constitute an acceleration in skin aging and are the result of decreased collagen content irregularities in the morphology of epidermal skin cells decreased ground substance between skin fibers and reduced capillaries and blood flow 70 71 The skin also becomes more dry during menopause which is due to reduced skin hydration and surface lipids sebum production 70 Along with chronological aging and photoaging estrogen deficiency in menopause is one of the three main factors that predominantly influences skin aging 70 Hormone replacement therapy consisting of systemic treatment with estrogen alone or in combination with a progestogen has well documented and considerable beneficial effects on the skin of postmenopausal women 70 71 These benefits include increased skin collagen content skin thickness and elasticity and skin hydration and surface lipids 70 71 Topical estrogen has been found to have similar beneficial effects on the skin 70 In addition a study has found that topical 2 progesterone cream significantly increases skin elasticity and firmness and observably decreases wrinkles in peri and postmenopausal women 71 Skin hydration and surface lipids on the other hand did not significantly change with topical progesterone 71 These findings suggest that progesterone like estrogen also has beneficial effects on the skin and may be independently protective against skin aging 71 Sexuality edit Libido edit See also Sexual motivation and hormones Progesterone and its neurosteroid active metabolite allopregnanolone appear to be importantly involved in libido in females 72 Homosexuality edit Dr Diana Fleischman of the University of Portsmouth and colleagues looked for a relationship between progesterone and sexual attitudes in 92 women Their research published in the Archives of Sexual Behavior found that women who had higher levels of progesterone scored higher on a questionnaire measuring homoerotic motivation They also found that men who had high levels of progesterone were more likely to have higher homoerotic motivation scores after affiliative priming compared to men with low levels of progesterone 73 74 75 76 Nervous system edit Progesterone like pregnenolone and dehydroepiandrosterone DHEA belongs to an important group of endogenous steroids called neurosteroids It can be metabolized within all parts of the central nervous system 77 Neurosteroids are neuromodulators and are neuroprotective neurogenic and regulate neurotransmission and myelination 78 The effects of progesterone as a neurosteroid are mediated predominantly through its interactions with non nuclear PRs namely the mPRs and PGRMC1 as well as certain other receptors such as the s1 and nACh receptors 79 Brain damage edit See also Progesterone medication Other uses Previous studies have shown that progesterone supports the normal development of neurons in the brain and that the hormone has a protective effect on damaged brain tissue It has been observed in animal models that females have reduced susceptibility to traumatic brain injury and this protective effect has been hypothesized to be caused by increased circulating levels of estrogen and progesterone in females 80 Proposed mechanism edit The mechanism of progesterone protective effects may be the reduction of inflammation that follows brain trauma and hemorrhage 81 82 Damage incurred by traumatic brain injury is believed to be caused in part by mass depolarization leading to excitotoxicity One way in which progesterone helps to alleviate some of this excitotoxicity is by blocking the voltage dependent calcium channels that trigger neurotransmitter release 83 It does so by manipulating the signaling pathways of transcription factors involved in this release Another method for reducing the excitotoxicity is by up regulating the GABAA a widespread inhibitory neurotransmitter receptor 84 Progesterone has also been shown to prevent apoptosis in neurons a common consequence of brain injury 85 It does so by inhibiting enzymes involved in the apoptosis pathway specifically concerning the mitochondria such as activated caspase 3 and cytochrome c Not only does progesterone help prevent further damage it has also been shown to aid in neuroregeneration 86 One of the serious effects of traumatic brain injury includes edema Animal studies show that progesterone treatment leads to a decrease in edema levels by increasing the concentration of macrophages and microglia sent to the injured tissue 83 87 This was observed in the form of reduced leakage from the blood brain barrier in secondary recovery in progesterone treated rats In addition progesterone was observed to have antioxidant properties reducing the concentration of oxygen free radicals faster than without 84 There is also evidence that the addition of progesterone can also help remyelinate damaged axons due to trauma restoring some lost neural signal conduction 84 Another way progesterone aids in regeneration includes increasing the circulation of endothelial progenitor cells in the brain 88 This helps new vasculature to grow around scar tissue which helps repair the area of insult Addiction edit Progesterone enhances the function of serotonin receptors in the brain so an excess or deficit of progesterone has the potential to result in significant neurochemical issues This provides an explanation for why some people resort to substances that enhance serotonin activity such as nicotine alcohol and cannabis when their progesterone levels fall below optimal levels 89 Sex differences in hormone levels may induce women to respond differently than men to nicotine When women undergo cyclic changes or different hormonal transition phases menopause pregnancy adolescence there are changes in their progesterone levels 90 Therefore females have an increased biological vulnerability to nicotine s reinforcing effects compared to males and progesterone may be used to counter this enhanced vulnerability This information supports the idea that progesterone can affect behavior 89 Similar to nicotine cocaine also increases the release of dopamine in the brain The neurotransmitter is involved in the reward center and is one of the main neurotransmitters involved with substance abuse and reliance In a study of cocaine users it was reported that progesterone reduced craving and the feeling of being stimulated by cocaine Thus progesterone was suggested as an agent that decreases cocaine craving by reducing the dopaminergic properties of the drug 91 Societal edit In a 2012 University of Amsterdam study of 120 women women s luteal phase higher levels of progesterone and increasing levels of estrogen was correlated with lower level of competitive behavior in gambling and math contest scenarios while their premenstrual phase sharply decreasing levels of progesterone and decreasing levels of estrogen was correlated with a higher level of competitive behavior 92 Other effects edit Progesterone also has a role in skin elasticity and bone strength in respiration in nerve tissue and in female sexuality and the presence of progesterone receptors in certain muscle and fat tissue may hint at a role in sexually dimorphic proportions of those 93 infringing link During pregnancy progesterone is said to decrease uterine irritability 94 During pregnancy progesterone helps to suppress immune responses of the mother to fetal antigens which prevents rejection of the fetus 94 Progesterone raises epidermal growth factor 1 EGF 1 levels a factor often used to induce proliferation and used to sustain cultures of stem cells 95 Progesterone increases core temperature thermogenic function during ovulation 96 97 Progesterone reduces spasm and relaxes smooth muscle Bronchi are widened and mucus regulated PRs are widely present in submucosal tissue Progesterone acts as an antiinflammatory agent and regulates the immune response Progesterone reduces gall bladder activity 98 Progesterone normalizes blood clotting and vascular tone zinc and copper levels cell oxygen levels and use of fat stores for energy Progesterone may affect gum health increasing risk of gingivitis gum inflammation 99 Progesterone appears to prevent endometrial cancer involving the uterine lining by regulating the effects of estrogen Progesterone plays an important role in the signaling of insulin release and pancreatic function and may affect the susceptibility to diabetes or gestational diabetes 100 101 Progesterone levels in the blood were found to be lower in women who had higher weight and higher BMI among those who became pregnant through in vitro fertilization 102 Current data shows that micronized progesterone which is chemically identical to the progesterone produced in women s bodies in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism blood clots in veins and ischemic stroke lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain However more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of myocardial infarctions heart attacks 103 There have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause 104 Despite suggestions for using hormone therapy to prevent loss of muscle mass in post menopausal women 50 and older menopausal hormone therapy involving either estrogen alone or estrogen and progesterone has not been found to preserve muscle mass 105 Menopausal hormone therapy also does not result in body weight reduction BMI reduction or change in glucose metabolism 106 Biochemistry editBiosynthesis edit nbsp Steroidogenesis showing progesterone among the progestogens in yellow area 107 In mammals progesterone like all other steroid hormones is synthesized from pregnenolone which itself is derived from cholesterol Cholesterol undergoes double oxidation to produce 22R hydroxycholesterol and then 20a 22R dihydroxycholesterol This vicinal diol is then further oxidized with loss of the side chain starting at position C22 to produce pregnenolone This reaction is catalyzed by cytochrome P450scc The conversion of pregnenolone to progesterone takes place in two steps First the 3b hydroxyl group is oxidized to a keto group and second the double bond is moved to C4 from C5 through a keto enol tautomerization reaction 108 This reaction is catalyzed by 3b hydroxysteroid dehydrogenase d5 4 isomerase Progesterone in turn is the precursor of the mineralocorticoid aldosterone and after conversion to 17a hydroxyprogesterone of cortisol and androstenedione Androstenedione can be converted to testosterone estrone and estradiol highlighting the critical role of progesterone in testosterone synthesis Pregnenolone and progesterone can also be synthesized by yeast 109 Approximately 25 mg of progesterone is secreted from the ovaries per day in women while the adrenal glands produce about 2 mg of progesterone per day 110 vte Production rates secretion rates clearance rates and blood levels of major sex hormones Sex Sex hormone Reproductivephase Bloodproduction rate Gonadalsecretion rate Metabolicclearance rate Reference range serum levels SI units Non SI unitsMen Androstenedione 2 8 mg day 1 6 mg day 2200 L day 2 8 7 3 nmol L 80 210 ng dLTestosterone 6 5 mg day 6 2 mg day 950 L day 6 9 34 7 nmol L 200 1000 ng dLEstrone 150 mg day 110 mg day 2050 L day 37 250 pmol L 10 70 pg mLEstradiol 60 mg day 50 mg day 1600 L day lt 37 210 pmol L 10 57 pg mLEstrone sulfate 80 mg day Insignificant 167 L day 600 2500 pmol L 200 900 pg mLWomen Androstenedione 3 2 mg day 2 8 mg day 2000 L day 3 1 12 2 nmol L 89 350 ng dLTestosterone 190 mg day 60 mg day 500 L day 0 7 2 8 nmol L 20 81 ng dLEstrone Follicular phase 110 mg day 80 mg day 2200 L day 110 400 pmol L 30 110 pg mLLuteal phase 260 mg day 150 mg day 2200 L day 310 660 pmol L 80 180 pg mLPostmenopause 40 mg day Insignificant 1610 L day 22 230 pmol L 6 60 pg mLEstradiol Follicular phase 90 mg day 80 mg day 1200 L day lt 37 360 pmol L 10 98 pg mLLuteal phase 250 mg day 240 mg day 1200 L day 699 1250 pmol L 190 341 pg mLPostmenopause 6 mg day Insignificant 910 L day lt 37 140 pmol L 10 38 pg mLEstrone sulfate Follicular phase 100 mg day Insignificant 146 L day 700 3600 pmol L 250 1300 pg mLLuteal phase 180 mg day Insignificant 146 L day 1100 7300 pmol L 400 2600 pg mLProgesterone Follicular phase 2 mg day 1 7 mg day 2100 L day 0 3 3 nmol L 0 1 0 9 ng mLLuteal phase 25 mg day 24 mg day 2100 L day 19 45 nmol L 6 14 ng mLNotes and sourcesNotes The concentration of a steroid in the circulation is determined by the rate at which it is secreted from glands the rate of metabolism of precursor or prehormones into the steroid and the rate at which it is extracted by tissues and metabolized The secretion rate of a steroid refers to the total secretion of the compound from a gland per unit time Secretion rates have been assessed by sampling the venous effluent from a gland over time and subtracting out the arterial and peripheral venous hormone concentration The metabolic clearance rate of a steroid is defined as the volume of blood that has been completely cleared of the hormone per unit time The production rate of a steroid hormone refers to entry into the blood of the compound from all possible sources including secretion from glands and conversion of prohormones into the steroid of interest At steady state the amount of hormone entering the blood from all sources will be equal to the rate at which it is being cleared metabolic clearance rate multiplied by blood concentration production rate metabolic clearance rate concentration If there is little contribution of prohormone metabolism to the circulating pool of steroid then the production rate will approximate the secretion rate Sources See template Distribution edit Progesterone binds extensively to plasma proteins including albumin 50 54 and transcortin 43 48 111 It has similar affinity for albumin relative to the PR 17 Metabolism edit The metabolism of progesterone is rapid and extensive and occurs mainly in the liver 112 113 114 though enzymes that metabolize progesterone are also expressed widely in the brain skin and various other extrahepatic tissues 77 115 Progesterone has an elimination half life of only approximately 5 minutes in circulation 112 The metabolism of progesterone is complex and it may form as many as 35 different unconjugated metabolites when it is ingested orally 114 116 Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases due to its double bond between the C4 and C5 positions and its two ketones at the C3 and C20 positions 114 The major metabolic pathway of progesterone is reduction by 5a reductase 77 and 5b reductase into the dihydrogenated 5a dihydroprogesterone and 5b dihydroprogesterone respectively 113 114 117 118 This is followed by the further reduction of these metabolites via 3a hydroxysteroid dehydrogenase and 3b hydroxysteroid dehydrogenase into the tetrahydrogenated allopregnanolone pregnanolone isopregnanolone and epipregnanolone 119 113 114 117 Subsequently 20a hydroxysteroid dehydrogenase and 20b hydroxysteroid dehydrogenase reduce these metabolites to form the corresponding hexahydrogenated pregnanediols eight different isomers in total 113 118 which are then conjugated via glucuronidation and or sulfation released from the liver into circulation and excreted by the kidneys into the urine 112 114 The major metabolite of progesterone in the urine is the 3a 5b 20a isomer of pregnanediol glucuronide which has been found to constitute 15 to 30 of an injection of progesterone 17 120 Other metabolites of progesterone formed by the enzymes in this pathway include 3a dihydroprogesterone 3b dihydroprogesterone 20a dihydroprogesterone and 20b dihydroprogesterone as well as various combination products of the enzymes aside from those already mentioned 17 114 120 121 Progesterone can also first be hydroxylated see below and then reduced 114 Endogenous progesterone is metabolized approximately 50 into 5a dihydroprogesterone in the corpus luteum 35 into 3b dihydroprogesterone in the liver and 10 into 20a dihydroprogesterone 122 Relatively small portions of progesterone are hydroxylated via 17a hydroxylase CYP17A1 and 21 hydroxylase CYP21A2 into 17a hydroxyprogesterone and 11 deoxycorticosterone 21 hydroxyprogesterone respectively 116 and pregnanetriols are formed secondarily to 17a hydroxylation 123 124 Even smaller amounts of progesterone may be also hydroxylated via 11b hydroxylase CYP11B1 and to a lesser extent via aldosterone synthase CYP11B2 into 11b hydroxyprogesterone 125 126 44 In addition progesterone can be hydroxylated in the liver by other cytochrome P450 enzymes which are not steroid specific 127 6b Hydroxylation which is catalyzed mainly by CYP3A4 is the major transformation and is responsible for approximately 70 of cytochrome P450 mediated progesterone metabolism 127 Other routes include 6a 16a and 16b hydroxylation 114 However treatment of women with ketoconazole a strong CYP3A4 inhibitor had minimal effects on progesterone levels producing only a slight and non significant increase and this suggests that cytochrome P450 enzymes play only a small role in progesterone metabolism 128 vte Metabolism of progesterone in humans 129 nbsp Progesterone 17a Hydroxyprogesterone 11 Deoxycorticosterone Pregnanetriols 8 isomers 5a Dihydroprogesterone 5b Dihydroprogesterone Allopregnanolone Isopregnanolone Pregnanolone Epipregnanolone Pregnanediols 8 isomers 17a Hydroxylase 21 Hydroxylase Multiple 5a Reductase 5b Reductase 3a HSD 3b HSD 3a HSD 3b HSD 20a HSD 20b HSD nbsp This diagram illustrates the metabolic pathways involved in the metabolism of progesterone in humans In addition to the transformations shown in the diagram conjugation specifically glucuronidation and sulfation occurs with metabolites of progesterone that have one or more available hydroxyl OH groups Levels edit nbsp Progesterone levels across the menstrual cycle in normally cycling and ovulatory women 130 The horizontal lines are the mean integrated levels for each curve The vertical line is mid cycle In women progesterone levels are relatively low during the preovulatory phase of the menstrual cycle rise after ovulation and are elevated during the luteal phase as shown in the diagram above Progesterone levels tend to be less than 2 ng mL prior to ovulation and greater than 5 ng mL after ovulation If pregnancy occurs human chorionic gonadotropin is released maintaining the corpus luteum and allowing it to maintain levels of progesterone Between 7 and 9 weeks the placenta begins to produce progesterone in place of the corpus luteum in a process called the luteal placental shift 131 After the luteal placental shift progesterone levels start to rise further and may reach 100 to 200 ng mL at term Whether a decrease in progesterone levels is critical for the initiation of labor has been argued and may be species specific After delivery of the placenta and during lactation progesterone levels are very low Progesterone levels are low in children and postmenopausal women 132 Adult males have levels similar to those in women during the follicular phase of the menstrual cycle Endogenous progesterone production rates and plasma progesterone levels Group P4 production P4 levelsPrepubertal children ND 0 06 0 5 ng mLPubertal girls Tanner stage I childhood Tanner stage II ages 8 12 Tanner stage III ages 10 13 Tanner stage IV ages 11 14 Tanner stage V ages 12 15 Follicular phase days 1 14 Luteal phase days 15 28 NDNDNDND NDND 0 22 lt 0 10 0 32 ng mL0 30 0 10 0 51 ng mL0 36 0 10 0 75 ng mL1 75 lt 0 10 25 0 ng mL 0 35 0 13 0 75 ng mL2 0 25 0 ng mLPremenopausal women Follicular phase days 1 14 Luteal phase days 15 28 Oral contraceptive anovulatory 0 75 5 4 mg day15 50 mg dayND 0 02 1 2 ng mL4 30 ng mL0 1 0 3 ng mLPostmenopausal womenOophorectomized womenOophorectomized and adrenalectomized women ND1 2 mg day lt 0 3 mg day 0 03 0 3 ng mL0 39 ng mLNDPregnant women First trimester weeks 1 12 Second trimester weeks 13 26 Third trimester weeks 27 40 Postpartum at 24 hours 55 mg day92 100 mg day190 563 mg dayND 9 75 ng mL17 146 ng mL55 255 ng mL19 ng mLMen 0 75 3 mg day 0 1 0 3 ng mLNotes Mean levels are given as a single value and ranges are given after in parentheses Sources 129 133 134 135 136 137 138 139 140 Ranges edit Blood test results should always be interpreted using the reference ranges provided by the laboratory that performed the results Example reference ranges are listed below Person type Reference range for blood testLower limit Upper limit UnitFemale menstrual cycle see diagram below Female postmenopausal lt 0 2 141 1 141 ng mL lt 0 6 142 3 142 nmol LFemale on oral contraceptives 0 34 141 0 92 141 ng mL1 1 142 2 9 142 nmol LMales 16 years 0 27 141 0 9 141 ng mL0 86 142 2 9 142 nmol LFemale or male 1 9 years 0 1 141 4 1 141 or 4 5 141 ng mL0 3 142 13 142 nmol LReference ranges for the blood content of progesterone during the menstrual cycle nbsp Progesterone levels during the menstrual cycle 143 The ranges denoted By biological stage may be used in closely monitored menstrual cycles in regard to other markers of its biological progression with the time scale being compressed or stretched to how much faster or slower respectively the cycle progresses compared to an average cycle The ranges denoted Inter cycle variability are more appropriate to use in non monitored cycles with only the beginning of menstruation known but where the woman accurately knows her average cycle lengths and time of ovulation and that they are somewhat averagely regular with the time scale being compressed or stretched to how much a woman s average cycle length is shorter or longer respectively than the average of the population The ranges denoted Inter woman variability are more appropriate to use when the average cycle lengths and time of ovulation are unknown but only the beginning of menstruation is given Sources edit Animal edit Progesterone is produced in high amounts in the ovaries by the corpus luteum from the onset of puberty to menopause and is also produced in smaller amounts by the adrenal glands after the onset of adrenarche in both males and females To a lesser extent progesterone is produced in nervous tissue especially in the brain and in adipose fat tissue as well During human pregnancy progesterone is produced in increasingly high amounts by the ovaries and placenta At first the source is the corpus luteum that has been rescued by the presence of human chorionic gonadotropin hCG from the conceptus However after the 8th week production of progesterone shifts to the placenta The placenta utilizes maternal cholesterol as the initial substrate and most of the produced progesterone enters the maternal circulation but some is picked up by the fetal circulation and used as substrate for fetal corticosteroids At term the placenta produces about 250 mg progesterone per day An additional animal source of progesterone is milk products After consumption of milk products the level of bioavailable progesterone goes up 144 Plants edit In at least one plant Juglans regia progesterone has been detected 145 In addition progesterone like steroids are found in Dioscorea mexicana Dioscorea mexicana is a plant that is part of the yam family native to Mexico 146 It contains a steroid called diosgenin that is taken from the plant and is converted into progesterone 147 Diosgenin and progesterone are also found in other Dioscorea species as well as in other plants that are not closely related such as fenugreek Another plant that contains substances readily convertible to progesterone is Dioscorea pseudojaponica native to Taiwan Research has shown that the Taiwanese yam contains saponins steroids that can be converted to diosgenin and thence to progesterone 148 Many other Dioscorea species of the yam family contain steroidal substances from which progesterone can be produced Among the more notable of these are Dioscorea villosa and Dioscorea polygonoides One study showed that the Dioscorea villosa contains 3 5 diosgenin 149 Dioscorea polygonoides has been found to contain 2 64 diosgenin as shown by gas chromatography mass spectrometry 150 Many of the Dioscorea species that originate from the yam family grow in countries that have tropical and subtropical climates 151 Medical use editMain articles Progesterone medication Pharmacodynamics of progesterone and Pharmacokinetics of progesterone Progesterone is used as a medication It is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women 116 152 It may also be used alone to treat menopausal symptoms Studies have shown that transdermal progesterone skin patch and oral micronized progesterone are effective treatments for certain symptoms of menopause such as hot flashes and night sweats which are otherwise referred to as vasomotor symptoms or VMS 153 It is also used in women to support pregnancy and fertility and to treat gynecological disorders 154 155 156 157 Progesterone has been shown to prevent miscarriage in women with 1 vaginal bleeding early in their current pregnancy and 2 a previous history of miscarriage 158 Progesterone can be taken by mouth through the vagina and by injection into muscle or fat among other routes 116 Chemistry edit nbsp A sample of progesteroneSee also List of neurosteroids Progesterone is a naturally occurring pregnane steroid and is also known as pregn 4 ene 3 20 dione 159 160 It has a double bond 4 ene between the C4 and C5 positions and two ketone groups 3 20 dione one at the C3 position and the other at the C20 position 159 160 Synthesis edit Progesterone is commercially produced by semisynthesis Two main routes are used one from yam diosgenin first pioneered by Marker in 1940 and one based on soy phytosterols scaled up in the 1970s Additional not necessarily economical semisyntheses of progesterone have also been reported starting from a variety of steroids For the example cortisone can be simultaneously deoxygenated at the C 17 and C 21 position by treatment with iodotrimethylsilane in chloroform to produce 11 keto progesterone ketogestin which in turn can be reduced at position 11 to yield progesterone 161 Marker semisynthesis edit Main article Marker degradation An economical semisynthesis of progesterone from the plant steroid diosgenin isolated from yams was developed by Russell Marker in 1940 for the Parke Davis pharmaceutical company 162 This synthesis is known as the Marker degradation nbsp The Marker semisynthesis of progesterone from diosgenin 162 The 16 DPA intermediate is important to the synthesis of many other medically important steroids A very similar approach can produce 16 DPA from solanine 163 Soy semisynthesis edit Progesterone can also be made from the stigmasterol found in soybean oil also c f Percy Julian nbsp Stigmasterol to progesterone synthesis 164 165 166 167 168 Total synthesis edit nbsp The Johnson total synthesis of progesterone 169 A total synthesis of progesterone was reported in 1971 by W S Johnson 169 The synthesis begins with reacting the phosphonium salt 7 with phenyl lithium to produce the phosphonium ylide 8 The ylide 8 is reacted with an aldehyde to produce the alkene 9 The ketal protecting groups of 9 are hydrolyzed to produce the diketone 10 which in turn is cyclized to form the cyclopentenone 11 The ketone of 11 is reacted with methyl lithium to yield the tertiary alcohol 12 which in turn is treated with acid to produce the tertiary cation 13 The key step of the synthesis is the p cation cyclization of 13 in which the B C and D rings of the steroid are simultaneously formed to produce 14 This step resembles the cationic cyclization reaction used in the biosynthesis of steroids and hence is referred to as biomimetic In the next step the enol orthoester is hydrolyzed to produce the ketone 15 The cyclopentene A ring is then opened by oxidizing with ozone to produce 16 Finally the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce progesterone 169 History editGeorge W Corner and Willard M Allen discovered the hormonal action of progesterone in 1929 17 170 171 172 By 1931 1932 nearly pure crystalline material of high progestational activity had been isolated from the corpus luteum of animals and by 1934 pure crystalline progesterone had been refined and obtained and the chemical structure of progesterone was determined 17 171 This was achieved by Adolf Butenandt at the Chemisches Institut of Technical University in Danzig who extracted this new compound from several thousand liters of urine 173 Chemical synthesis of progesterone from stigmasterol and pregnanediol was accomplished later that year 171 174 Up to this point progesterone known generically as corpus luteum hormone had been being referred to by several groups by different names including corporin lutein luteosterone and progestin 17 175 In 1935 at the time of the Second International Conference on the Standardization of Sex Hormones in London England a compromise was made between the groups and the name progesterone progestational steroidal ketone was created 17 176 Veterinary use edit The use of progesterone tests in dog breeding to pinpoint ovulation is becoming more widely used There are several tests available but the most reliable test is a blood test with blood drawn by a veterinarian and sent to a lab for processing Results can usually be obtained with 24 to 72 hours The rationale for using progesterone tests is that increased numbers begin in close proximity to preovulatory surge in gonadotrophins and continue through ovulation and estrus When progesterone levels reach certain levels they can signal the stage of estrus the female is Prediction of birth date of the pending litter can be very accurate if ovulation date is known Puppies deliver with a day or two of 9 weeks gestation in most cases It is not possible to determine pregnancy using progesterone tests once a breeding has taken place however This is due to the fact that in dogs progesterone levels remain elevated throughout the estrus period 177 Pricing editPricing for progesterone can vary depending location insurance coverage discount coupons quantity shortages manufacturers brand or generic versions different pharmacies and so on As of currently 30 capsules of 100 mg of the generic version Prometrium from CVS Pharmacy is around 40 without any discounts or insurance applied The brand version Progesterone is around 450 for 30 capsules without any discounts or insurance applied 178 In comparison Walgreens offers 30 capsules of 100 mg in the generic version for 51 without insurance or coupons applied The brand name costs around 431 for 30 capsules of 100 mg 179 References edit nbsp This article incorporates text available under the CC BY SA 3 0 license a b Jameson JL De Groot LJ 25 February 2015 Endocrinology Adult and Pediatric E Book Elsevier Health Sciences p 2179 ISBN 978 0 323 32195 2 Adler N Pfaff D Goy RW 6 December 2012 Handbook of Behavioral Neurobiology Volume 7 Reproduction 1st ed New York Plenum Press p 189 ISBN 978 1 4684 4834 4 Retrieved 4 July 2015 progesterone CHEBI 17026 ChEBI European Molecular Biology Laboratory EBI Retrieved 4 July 2015 Progesterone msds a b Stanczyk FZ September 2002 Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception Reviews in Endocrine amp Metabolic Disorders 3 3 211 224 doi 10 1023 A 1020072325818 PMID 12215716 S2CID 27018468 a b c Simon JA Robinson DE Andrews MC Hildebrand JR Rocci ML Blake RE Hodgen GD July 1993 The absorption of oral micronized progesterone the effect of food dose proportionality and comparison with intramuscular progesterone Fertility and Sterility 60 1 26 33 doi 10 1016 S0015 0282 16 56031 2 PMID 8513955 Fritz MA Speroff L 28 March 2012 Clinical Gynecologic Endocrinology and Infertility Lippincott Williams amp Wilkins pp 44 ISBN 978 1 4511 4847 3 Marshall WJ Bangert SK 2008 Clinical Chemistry Elsevier Health Sciences pp 192 ISBN 978 0 7234 3455 9 Yamazaki H Shimada T October 1997 Progesterone and testosterone hydroxylation by cytochromes P450 2C19 2C9 and 3A4 in human liver microsomes Archives of Biochemistry and Biophysics 346 1 161 169 doi 10 1006 abbi 1997 0302 PMID 9328296 McKay GA Walters MR 6 February 2013 Lecture Notes Clinical Pharmacology and Therapeutics John Wiley amp Sons p 33 ISBN 978 1 118 34489 7 Zutshi V Rathore AM Sharma K 1 January 2005 Hormones in Obstetrics and Gynaecology Jaypee Brothers Publishers p 74 ISBN 978 81 8061 427 9 permanent dead link a b Cometti B November 2015 Pharmaceutical and clinical development of a novel progesterone formulation Acta Obstetricia et Gynecologica Scandinavica 94 Suppl 161 28 37 doi 10 1111 aogs 12765 PMID 26342177 S2CID 31974637 a b c King TL Brucker MC 25 October 2010 Pharmacology for Women s Health Jones amp Bartlett Publishers pp 372 373 ISBN 978 1 4496 5800 7 a b Baulieu E Schumacher M 2000 Progesterone as a neuroactive neurosteroid with special reference to the effect of progesterone on myelination Steroids 65 10 11 605 612 doi 10 1016 s0039 128x 00 00173 2 PMID 11108866 S2CID 14952168 Prior JC April 2019 Progesterone Is Important for Transgender Women s Therapy Applying Evidence for the Benefits of Progesterone in Ciswomen The Journal of Clinical Endocrinology and Metabolism 104 4 1181 1186 doi 10 1210 jc 2018 01777 PMID 30608551 S2CID 58620122 Evidence has accrued that normal progesterone and ovulation as well as physiological estradiol levels is necessary during ciswomen s premenopausal menstrual cycles for current fertility and long term health transgender women may require progesterone therapy and similar potential physiological benefits Fischer J Ganellin CR 2006 Analogue based Drug Discovery John Wiley amp Sons p 47X ISBN 9783527607495 a b c d e f g h Josimovich JB 11 November 2013 Gynecologic Endocrinology Springer Science amp Business Media pp 9 25 29 ISBN 978 1 4613 2157 6 Thomas P Pang Y 2012 Membrane progesterone receptors evidence for neuroprotective neurosteroid signaling and neuroendocrine functions in neuronal cells Neuroendocrinology 96 2 162 171 doi 10 1159 000339822 PMC 3489003 PMID 22687885 Valadez Cosmes P Vazquez Martinez ER Cerbon M Camacho Arroyo I October 2016 Membrane progesterone receptors in reproduction and cancer Molecular and Cellular Endocrinology 434 166 175 doi 10 1016 j mce 2016 06 027 PMID 27368976 S2CID 3826650 Meyer C Schmid R Schmieding K Falkenstein E Wehling M February 1998 Characterization of high affinity progesterone binding membrane proteins by anti peptide antiserum Steroids 63 2 111 116 doi 10 1016 s0039 128x 97 00143 8 PMID 9516722 S2CID 40096058 Kabe Y Handa H Suematsu M July 2018 Function and structural regulation of the carbon monoxide CO responsive membrane protein PGRMC1 Journal of Clinical Biochemistry and Nutrition 63 1 12 17 doi 10 3164 jcbn 17 132 PMC 6064819 PMID 30087538 Ryu CS Klein K Zanger UM 27 March 2017 Membrane Associated Progesterone Receptors Promiscuous Proteins with Pleiotropic Functions Focus on Interactions with Cytochromes P450 Frontiers in Pharmacology 8 159 doi 10 3389 fphar 2017 00159 PMC 5366339 PMID 28396637 Maurice T Urani A Phan VL Romieu P November 2001 The interaction between neuroactive steroids and the sigma1 receptor function behavioral consequences and therapeutic opportunities Brain Research Brain Research Reviews 37 1 3 116 132 doi 10 1016 s0165 0173 01 00112 6 PMID 11744080 S2CID 44931783 Johannessen M Fontanilla D Mavlyutov T Ruoho AE Jackson MB February 2011 Antagonist action of progesterone at s receptors in the modulation of voltage gated sodium channels American Journal of Physiology Cell Physiology 300 2 C328 C337 doi 10 1152 ajpcell 00383 2010 PMC 3043630 PMID 21084640 a b Rupprecht R Reul JM van Steensel B Spengler D Soder M Berning B et al October 1993 Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands European Journal of Pharmacology 247 2 145 154 doi 10 1016 0922 4106 93 90072 H PMID 8282004 Elger W Beier S Pollow K Garfield R Shi SQ Hillisch A November 2003 Conception and pharmacodynamic profile of drospirenone Steroids 68 10 13 891 905 doi 10 1016 j steroids 2003 08 008 PMID 14667981 S2CID 41756726 Attardi BJ Zeleznik A Simhan H Chiao JP Mattison DR Caritis SN December 2007 Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone 17 alpha hydroxyprogesterone caproate and related progestins American Journal of Obstetrics and Gynecology 197 6 599 e1 599 e7 doi 10 1016 j ajog 2007 05 024 PMC 2278032 PMID 18060946 Lei K Chen L Georgiou EX Sooranna SR Khanjani S Brosens JJ et al 2012 Progesterone acts via the nuclear glucocorticoid receptor to suppress IL 1b induced COX 2 expression in human term myometrial cells PLOS ONE 7 11 e50167 Bibcode 2012PLoSO 750167L doi 10 1371 journal pone 0050167 PMC 3509141 PMID 23209664 Paul SM Purdy RH March 1992 Neuroactive steroids FASEB Journal 6 6 2311 2322 doi 10 1096 fasebj 6 6 1347506 PMID 1347506 S2CID 221753076 Kliewer SA Goodwin B Willson TM October 2002 The nuclear pregnane X receptor a key regulator of xenobiotic metabolism Endocrine Reviews 23 5 687 702 doi 10 1210 er 2001 0038 PMID 12372848 Lehmann JM McKee DD Watson MA Willson TM Moore JT Kliewer SA September 1998 The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions The Journal of Clinical Investigation 102 5 1016 1023 doi 10 1172 JCI3703 PMC 508967 PMID 9727070 Meanwell NA 8 December 2014 Tactics in Contemporary Drug Design Springer pp 161 ISBN 978 3 642 55041 6 a b Legato MJ Bilezikian JP 2004 Principles of Gender specific Medicine Gulf Professional Publishing pp 146 ISBN 978 0 12 440906 4 Williams DA 24 January 2012 Drug Metabolism In Lemke TL Williams DA eds Foye s Principles of Medicinal Chemistry Lippincott Williams amp Wilkins p 164 ISBN 978 1 60913 345 0 Estrogens Advances in Research and Application 2013 Edition ScholarlyBrief ScholarlyEditions 21 June 2013 pp 4 ISBN 978 1 4816 7550 5 Strunker T Goodwin N Brenker C Kashikar ND Weyand I Seifert R Kaupp UB March 2011 The CatSper channel mediates progesterone induced Ca2 influx in human sperm Nature 471 7338 382 386 Bibcode 2011Natur 471 382S doi 10 1038 nature09769 PMID 21412338 S2CID 4431334 Lishko PV Botchkina IL Kirichok Y March 2011 Progesterone activates the principal Ca2 channel of human sperm Nature 471 7338 387 391 Bibcode 2011Natur 471 387L doi 10 1038 nature09767 PMID 21412339 S2CID 4340309 Prior JC 2020 Women s reproductive system as balanced estradiol and progesterone actions A revolutionary paradigm shifting concept in women s health Drug Discovery Today Disease Models 32 Part B 31 40 doi 10 1016 j ddmod 2020 11 005 Kastner P Krust A Turcotte B Stropp U Tora L Gronemeyer H Chambon P May 1990 Two distinct estrogen regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B The EMBO Journal 9 5 1603 1614 doi 10 1002 j 1460 2075 1990 tb08280 x PMC 551856 PMID 2328727 a b Cline JM Wood CE 1 January 2006 Hallam SZ Osuch JR eds Hormonal effects on the mammary gland of postmenopausal nonhuman primates Breast Disease IOS Press 24 59 70 doi 10 3233 bd 2006 24105 ISBN 978 1 58603 653 9 PMID 16917139 a b Johnson LR 2003 Essential Medical Physiology Academic Press p 770 ISBN 978 0 12 387584 6 a b Coad J Dunstall M 2011 Anatomy and Physiology for Midwives with Pageburst online access 3 Anatomy and Physiology for Midwives Elsevier Health Sciences p 413 ISBN 978 0 7020 3489 3 Landau RL Bergenstal DM Lugibihl K Kascht ME October 1955 The metabolic effects of progesterone in man The Journal of Clinical Endocrinology and Metabolism 15 10 1194 1215 doi 10 1210 jcem 15 10 1194 PMID 13263410 a b c Masiutin M Yadav M 2023 Alternative androgen pathways WikiJournal of Medicine 10 X doi 10 15347 WJM 2023 003 S2CID 257943362 a b O Shaughnessy PJ Antignac JP Le Bizec B Morvan ML Svechnikov K Soder O et al February 2019 Alternative backdoor androgen production and masculinization in the human fetus PLOS Biology 17 2 e3000002 doi 10 1371 journal pbio 3000002 PMC 6375548 PMID 30763313 Fluck CE Pandey AV May 2014 Steroidogenesis of the testis new genes and pathways Annales d Endocrinologie 75 2 40 47 doi 10 1016 j ando 2014 03 002 PMID 24793988 Zachmann M February 1996 Prismatic cases 17 20 desmolase 17 20 lyase deficiency The Journal of Clinical Endocrinology and Metabolism 81 2 457 459 doi 10 1210 jcem 81 2 8636249 PMID 8636249 Correia JN Conner SJ Kirkman Brown JC May 2007 Non genomic steroid actions in human spermatozoa Persistent tickling from a laden environment Seminars in Reproductive Medicine 25 3 208 219 doi 10 1055 s 2007 973433 PMID 17447210 S2CID 260318879 Kirkman Brown JC Bray C Stewart PM Barratt CL Publicover SJ June 2000 Biphasic elevation of Ca 2 i in individual human spermatozoa exposed to progesterone Developmental Biology 222 2 326 335 doi 10 1006 dbio 2000 9729 PMID 10837122 Kirkman Brown JC Barratt CL Publicover SJ March 2004 Slow calcium oscillations in human spermatozoa The Biochemical Journal 378 Pt 3 827 832 doi 10 1042 BJ20031368 PMC 1223996 PMID 14606954 Harper CV Barratt CL Publicover SJ October 2004 Stimulation of human spermatozoa with progesterone gradients to simulate approach to the oocyte Induction of Ca 2 i oscillations and cyclical transitions in flagellar beating The Journal of Biological Chemistry 279 44 46315 46325 doi 10 1074 jbc M401194200 PMID 15322137 Marieb E 2013 Anatomy amp physiology Benjamin Cummings p 903 ISBN 9780321887603 Tosti E Di Cosmo A Cuomo A Di Cristo C Gragnaniello G May 2001 Progesterone induces activation in Octopus vulgaris spermatozoa Molecular Reproduction and Development 59 1 97 105 doi 10 1002 mrd 1011 PMID 11335951 S2CID 28390608 a b Bowen R 6 August 2000 Placental Hormones Retrieved 12 March 2008 Patel B Elguero S Thakore S Dahoud W Bedaiwy M Mesiano S 2014 Role of nuclear progesterone receptor isoforms in uterine pathophysiology Human Reproduction Update 21 2 155 173 doi 10 1093 humupd dmu056 PMC 4366574 PMID 25406186 a b Di Renzo GC Giardina I Clerici G Brillo E Gerli S July 2016 Progesterone in normal and pathological pregnancy Hormone Molecular Biology and Clinical Investigation 27 1 35 48 doi 10 1515 hmbci 2016 0038 PMID 27662646 S2CID 32239449 Care A Nevitt SJ Medley N Donegan S Good L Hampson L et al February 2022 Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk systematic review and network meta analysis BMJ 376 e064547 doi 10 1136 bmj 2021 064547 PMC 8845039 PMID 35168930 Macias H Hinck L 2012 Mammary gland development Wiley Interdisciplinary Reviews Developmental Biology 1 4 533 557 doi 10 1002 wdev 35 PMC 3404495 PMID 22844349 a b c Hilton HN Graham JD Clarke CL September 2015 Minireview Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer A Tale of Two Scenarios Molecular Endocrinology 29 9 1230 1242 doi 10 1210 me 2015 1152 PMC 5414684 PMID 26266959 Barbieri RL 13 September 2013 The Breast In Strauss JF Barbieri RL eds Yen and Jaffe s Reproductive Endocrinology Elsevier Health Sciences pp 236 ISBN 978 1 4557 2758 2 Scaling AL Prossnitz ER Hathaway HJ June 2014 GPER mediates estrogen induced signaling and proliferation in human breast epithelial cells and normal and malignant breast Hormones amp Cancer 5 3 146 160 doi 10 1007 s12672 014 0174 1 PMC 4091989 PMID 24718936 a b c d e Aupperlee MD Leipprandt JR Bennett JM Schwartz RC Haslam SZ May 2013 Amphiregulin mediates progesterone induced mammary ductal development during puberty Breast Cancer Research 15 3 R44 doi 10 1186 bcr3431 PMC 3738150 PMID 23705924 a b Kuhl H Schneider HP August 2013 Progesterone promoter or inhibitor of breast cancer Climacteric 16 Suppl 1 54 68 doi 10 3109 13697137 2013 768806 PMID 23336704 S2CID 20808536 a b c Trabert B Sherman ME Kannan N Stanczyk FZ April 2020 Progesterone and Breast Cancer Endocrine Reviews 41 2 320 344 doi 10 1210 endrev bnz001 PMC 7156851 PMID 31512725 Collaborative Group on Hormonal Factors in Breast Cancer September 2019 Type and timing of menopausal hormone therapy and breast cancer risk individual participant meta analysis of the worldwide epidemiological evidence Lancet 394 10204 1159 1168 doi 10 1016 S0140 6736 19 31709 X PMC 6891893 PMID 31474332 Stute P Wildt L Neulen J April 2018 The impact of micronized progesterone on breast cancer risk a systematic review PDF Climacteric 21 2 111 122 doi 10 1080 13697137 2017 1421925 PMID 29384406 S2CID 3642971 Asi N Mohammed K Haydour Q Gionfriddo MR Vargas OL Prokop LJ et al July 2016 Progesterone vs synthetic progestins and the risk of breast cancer a systematic review and meta analysis Systematic Reviews 5 1 121 doi 10 1186 s13643 016 0294 5 PMC 4960754 PMID 27456847 Gompel A Plu Bureau G August 2018 Progesterone progestins and the breast in menopause treatment Climacteric 21 4 326 332 doi 10 1080 13697137 2018 1476483 PMID 29852797 S2CID 46922084 Davey DA October 2018 Menopausal hormone therapy a better and safer future Climacteric 21 5 454 461 doi 10 1080 13697137 2018 1439915 PMID 29526116 S2CID 3850275 a b c d e f g h Raine Fenning NJ Brincat MP Muscat Baron Y 2003 Skin aging and menopause implications for treatment American Journal of Clinical Dermatology 4 6 371 378 doi 10 2165 00128071 200304060 00001 PMID 12762829 S2CID 20392538 a b c d e f g h Holzer G Riegler E Honigsmann H Farokhnia S Schmidt JB September 2005 Effects and side effects of 2 progesterone cream on the skin of peri and postmenopausal women results from a double blind vehicle controlled randomized study The British Journal of Dermatology 153 3 626 634 doi 10 1111 j 1365 2133 2005 06685 x PMID 16120154 S2CID 6077829 King SR 9 November 2012 Neurosteroids and the Nervous System Springer Science amp Business Media pp 44 46 ISBN 978 1 4614 5559 2 Fleischman DS Fessler DM Cholakians AE July 2015 Testing the Affiliation Hypothesis of Homoerotic Motivation in Humans The Effects of Progesterone and Priming Archives of Sexual Behavior 44 5 1395 1404 doi 10 1007 s10508 014 0436 6 PMID 25420899 S2CID 9864224 Homosexuality may help us bond UoP News Archived from the original on 2 July 2019 Retrieved 2 July 2019 Having homosexual thoughts is an essential part of human evolution study suggests The Telegraph 25 November 2014 New Study Identifies Evolutionary Basis Of Homosexuality HuffPost 26 November 2014 a b c Hanukoglu I Karavolas HJ Goy RW April 1977 Progesterone metabolism in the pineal brain stem thalamus and corpus callosum of the female rat Brain Research 125 2 313 324 doi 10 1016 0006 8993 77 90624 2 PMID 558037 S2CID 35814845 Schumacher M Guennoun R Robert F Carelli C Gago N Ghoumari A et al June 2004 Local synthesis and dual actions of progesterone in the nervous system neuroprotection and myelination Growth Hormone amp IGF Research 14 Suppl A S18 S33 doi 10 1016 j ghir 2004 03 007 PMID 15135772 Singh M Su C Ng S September 2013 Non genomic mechanisms of progesterone action in the brain Frontiers in Neuroscience 7 159 doi 10 3389 fnins 2013 00159 PMC 3776940 PMID 24065876 Roof RL Hall ED May 2000 Gender differences in acute CNS trauma and stroke neuroprotective effects of estrogen and progesterone Journal of Neurotrauma 17 5 367 388 doi 10 1089 neu 2000 17 367 PMID 10833057 Pan DS Liu WG Yang XF Cao F October 2007 Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury Biomedical and Environmental Sciences 20 5 432 438 PMID 18188998 Jiang C Zuo F Wang Y Wan J Yang Z Lu H et al June 2016 Progesterone exerts neuroprotective effects and improves long term neurologic outcome after intracerebral hemorrhage in middle aged mice Neurobiology of Aging 42 13 24 doi 10 1016 j neurobiolaging 2016 02 029 PMC 4857017 PMID 27143417 a b Luoma JI Stern CM Mermelstein PG August 2012 Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone mediated neuroprotection The Journal of Steroid Biochemistry and Molecular Biology 131 1 2 30 36 doi 10 1016 j jsbmb 2011 11 002 PMC 3303940 PMID 22101209 a b c Stein DG March 2008 Progesterone exerts neuroprotective effects after brain injury Brain Research Reviews 57 2 386 397 doi 10 1016 j brainresrev 2007 06 012 PMC 2699575 PMID 17826842 Espinoza TR Wright DW 2011 The role of progesterone in traumatic brain injury The Journal of Head Trauma Rehabilitation 26 6 497 499 doi 10 1097 HTR 0b013e31823088fa PMC 6025750 PMID 22088981 Jiang C Zuo F Wang Y Lu H Yang Q Wang J January 2016 Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke Molecular Neurobiology 54 1 571 581 doi 10 1007 s12035 015 9651 y PMC 4938789 PMID 26746666 Herson PS Koerner IP Hurn PD May 2009 Sex sex steroids and brain injury Seminars in Reproductive Medicine 27 3 229 239 doi 10 1055 s 0029 1216276 PMC 2675922 PMID 19401954 Li Z Wang B Kan Z Zhang B Yang Z Chen J et al January 2012 Progesterone increases circulating endothelial progenitor cells and induces neural regeneration after traumatic brain injury in aged rats Journal of Neurotrauma 29 2 343 353 doi 10 1089 neu 2011 1807 PMC 3261789 PMID 21534727 a b Lynch WJ Sofuoglu M December 2010 Role of progesterone in nicotine addiction evidence from initiation to relapse Experimental and Clinical Psychopharmacology 18 6 451 461 doi 10 1037 a0021265 PMC 3638762 PMID 21186920 Cosgrove KP Esterlis I McKee SA Bois F Seibyl JP Mazure CM et al April 2012 Sex differences in availability of b2 nicotinic acetylcholine receptors in recently abstinent tobacco smokers Archives of General Psychiatry 69 4 418 427 doi 10 1001 archgenpsychiatry 2011 1465 PMC 3508698 PMID 22474108 Mello NK Knudson IM Kelly M Fivel PA Mendelson JH October 2011 Effects of progesterone and testosterone on cocaine self administration and cocaine discrimination by female rhesus monkeys Neuropsychopharmacology 36 11 2187 2199 doi 10 1038 npp 2011 130 PMC 3176575 PMID 21796112 Buser T 1 June 2012 The impact of the menstrual cycle and hormonal contraceptives on competitiveness PDF Journal of Economic Behavior amp Organization Gender Differences in Risk Aversion and Competition 83 1 1 10 doi 10 1016 j jebo 2011 06 006 ISSN 0167 2681 Sriram D 2007 Medicinal Chemistry New Delhi Dorling Kindersley India Pvt Ltd p 432 ISBN 978 81 317 0031 0 a b Blackburn S 14 April 2014 Maternal Fetal amp Neonatal Physiology Elsevier Health Sciences pp 92 ISBN 978 0 323 29296 2 Faivre EJ Lange CA January 2007 Progesterone receptors upregulate Wnt 1 to induce epidermal growth factor receptor transactivation and c Src dependent sustained activation of Erk1 2 mitogen activated protein kinase in breast cancer cells Molecular and Cellular Biology 27 2 466 480 doi 10 1128 MCB 01539 06 PMC 1800800 PMID 17074804 Nosek TM Section 5 5ch9 s5ch9 13 Essentials of Human Physiology Archived from the original on 24 March 2016 Rothchild I 1969 Salhanick HA Kipnis DM Wiele RL eds The Physiologic Basis for the Temperature Raising Effect of Progesterone Metabolic Effects of Gonadal Hormones and Contraceptive Steroids Boston MA Springer US pp 668 675 doi 10 1007 978 1 4684 1782 1 49 ISBN 978 1 4684 1782 1 retrieved 22 March 2021 Hould FS Fried GM Fazekas AG Tremblay S Mersereau WA December 1988 Progesterone receptors regulate gallbladder motility The Journal of Surgical Research 45 6 505 512 doi 10 1016 0022 4804 88 90137 0 PMID 3184927 Hormones and Oral Health WebMD Picard F Wanatabe M Schoonjans K Lydon J O Malley BW Auwerx J November 2002 Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta cell proliferation Proceedings of the National Academy of Sciences of the United States of America 99 24 15644 15648 doi 10 1073 pnas 202612199 PMC 137770 PMID 12438645 Brănisteanu DD Mathieu C March 2003 Progesterone in gestational diabetes mellitus guilty or not guilty Trends in Endocrinology and Metabolism 14 2 54 56 doi 10 1016 S1043 2760 03 00003 1 PMID 12591170 S2CID 38209977 Whynott RM Summers KM Jakubiak M Van Voorhis BJ Mejia RB June 2021 The effect of weight and body mass index on serum progesterone values and live birth rate in cryopreserved in vitro fertilization cycles F amp S Reports 2 2 195 200 doi 10 1016 j xfre 2021 02 005 PMC 8267385 PMID 34278354 Kaemmle LM Stadler A Janka H von Wolff M Stute P August 2022 The impact of micronized progesterone on cardiovascular events a systematic review Climacteric 25 4 327 336 doi 10 1080 13697137 2021 2022644 PMID 35112635 S2CID 246487187 Gasser S Heidemeyer K von Wolff M Stute P June 2021 Impact of progesterone on skin and hair in menopause a comprehensive review Climacteric 24 3 229 235 doi 10 1080 13697137 2020 1838476 PMID 33527841 S2CID 231757325 Javed AA Mayhew AJ Shea AK Raina P August 2019 Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women A Systematic Review and Meta analysis JAMA Network Open 2 8 e1910154 doi 10 1001 jamanetworkopen 2019 10154 PMC 6716293 PMID 31461147 Coquoz A Gruetter C Stute P April 2019 Impact of micronized progesterone on body weight body mass index and glucose metabolism a systematic review Climacteric 22 2 148 161 doi 10 1080 13697137 2018 1514003 PMID 30477366 S2CID 53782622 Haggstrom M Richfield D 2014 Diagram of the pathways of human steroidogenesis WikiJournal of Medicine 1 1 doi 10 15347 wjm 2014 005 ISSN 2002 4436 Bewick PM 2002 Medicinal natural products a biosynthetic approach New York Wiley p 244 ISBN 0 471 49641 3 Duport C Spagnoli R Degryse E Pompon D February 1998 Self sufficient biosynthesis of pregnenolone and progesterone in engineered yeast Nature Biotechnology 16 2 186 189 doi 10 1038 nbt0298 186 PMID 9487528 S2CID 852617 Zavod RM 24 January 2012 Women s Health In Lemke TL Williams DA eds Foye s Principles of Medicinal Chemistry Lippincott Williams amp Wilkins pp 1397 ISBN 978 1 60913 345 0 Progesterone Drugs com retrieved 23 August 2015 a b c Falcone T Hurd WW 2007 Clinical Reproductive Medicine and Surgery Elsevier Health Sciences pp 22 ISBN 978 0 323 03309 1 a b c d Cupps PT 20 February 1991 Reproduction in Domestic Animals Elsevier pp 101 ISBN 978 0 08 057109 6 a b c d e f g h i Stanczyk FZ November 2003 All progestins are not created equal Steroids 68 10 13 879 890 doi 10 1016 j steroids 2003 08 003 PMID 14667980 S2CID 44601264 Dowd FJ Johnson B Mariotti A 3 September 2016 Pharmacology and Therapeutics for Dentistry Elsevier Health Sciences pp 448 ISBN 978 0 323 44595 5 a b c d Kuhl H August 2005 Pharmacology of estrogens and progestogens influence of different routes of administration Climacteric 8 Suppl 1 3 63 doi 10 1080 13697130500148875 PMID 16112947 S2CID 24616324 a b Plant TM Zeleznik AJ 15 November 2014 Knobil and Neill s Physiology of Reproduction Academic Press pp 304 ISBN 978 0 12 397769 4 a b Santoro NF Neal Perry G 11 September 2010 Amenorrhea A Case Based Clinical Guide Springer Science amp Business Media pp 13 ISBN 978 1 60327 864 5 Reddy DS 2010 Neurosteroids Sex Differences in the Human Brain their Underpinnings and Implications Progress in Brain Research Vol 186 Elsevier pp 113 37 doi 10 1016 B978 0 444 53630 3 00008 7 ISBN 9780444536303 PMC 3139029 PMID 21094889 a b Baulieu E Kelly PA 30 November 1990 Hormones From Molecules to Disease Springer Science amp Business Media pp 401 ISBN 978 0 412 02791 8 Beranic N Gobec S Rizner TL May 2011 Progestins as inhibitors of the human 20 ketosteroid reductases AKR1C1 and AKR1C3 Chemico Biological Interactions 191 1 3 227 233 Bibcode 2011CBI 191 227B doi 10 1016 j cbi 2010 12 012 PMID 21182831 Anderson GD Odegard PS October 2004 Pharmacokinetics of estrogen and progesterone in chronic kidney disease Advances in Chronic Kidney Disease 11 4 357 360 doi 10 1053 j ackd 2004 07 001 PMID 15492972 Greenblatt JM Brogan K 27 April 2016 Integrative Therapies for Depression Redefining Models for Assessment Treatment and Prevention CRC Press pp 201 ISBN 978 1 4987 0230 0 Graham C 2 December 2012 Reproductive Biology of the Great Apes Comparative and Biomedical Perspectives Elsevier pp 179 ISBN 978 0 323 14971 6 Strushkevich N Gilep AA Shen L Arrowsmith CH Edwards AM Usanov SA Park HW February 2013 Structural insights into aldosterone synthase substrate specificity and targeted inhibition Molecular Endocrinology 27 2 315 324 doi 10 1210 me 2012 1287 PMC 5417327 PMID 23322723 van Rooyen D Gent R Barnard L Swart AC April 2018 The in vitro metabolism of 11b hydroxyprogesterone and 11 ketoprogesterone to 11 ketodihydrotestosterone in the backdoor pathway The Journal of Steroid Biochemistry and Molecular Biology 178 203 212 doi 10 1016 j jsbmb 2017 12 014 PMID 29277707 S2CID 3700135 a b de Azevedo Piccinato C 2008 Regulation of Steroid Metabolism and the Hepatic Transcriptome by Estradiol and Progesterone pp 24 25 ISBN 978 1 109 04632 8 permanent dead link Akalin S January 1991 Effects of ketoconazole in hirsute women Acta Endocrinologica 124 1 19 22 doi 10 1530 acta 0 1240019 PMID 1825737 S2CID 9831739 a b Aufrere MB Benson H June 1976 Progesterone an overview and recent advances Journal of Pharmaceutical Sciences 65 6 783 800 doi 10 1002 jps 2600650602 PMID 945344 Stricker R Eberhart R Chevailler MC Quinn FA Bischof P Stricker R 2006 Establishment of detailed reference values for luteinizing hormone follicle stimulating hormone estradiol and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer Clinical Chemistry and Laboratory Medicine 44 7 883 887 doi 10 1515 CCLM 2006 160 PMID 16776638 S2CID 524952 Csapo AI Pulkkinen MO Wiest WG March 1973 Effects of luteectomy and progesterone replacement therapy in early pregnant patients American Journal of Obstetrics and Gynecology 115 6 759 765 doi 10 1016 0002 9378 73 90517 6 PMID 4688578 NIH Clinical Center 16 August 2004 Progesterone Historical Reference Ranges United States National Institutes of Health Archived from the original on 9 January 2009 Retrieved 12 March 2008 Chernecky CC Berger BJ 31 October 2012 Laboratory Tests and Diagnostic Procedures E Book Elsevier Health Sciences pp 908 ISBN 978 1 4557 4502 9 Becker KL 2001 Principles and Practice of Endocrinology and Metabolism Lippincott Williams amp Wilkins pp 889 940 ISBN 978 0 7817 1750 2 Josimovich JB 11 November 2013 Gynecologic Endocrinology Springer Science amp Business Media pp 9 25 29 139 ISBN 978 1 4613 2157 6 van Keep P Utian W 6 December 2012 The Premenstrual Syndrome Proceedings of a workshop held during the Sixth International Congress of Psychosomatic Obstetrics and Gynecology Berlin September 1980 Springer Science amp Business Media pp 51 52 ISBN 978 94 011 6255 5 Strauss JF Barbieri RL 2009 Yen and Jaffe s Reproductive Endocrinology Physiology Pathophysiology and Clinical Management Elsevier Health Sciences pp 807 ISBN 978 1 4160 4907 4 Bajaj L Berman S 1 January 2011 Berman s Pediatric Decision Making Elsevier Health Sciences pp 160 ISBN 978 0 323 05405 8 Lauritzen C 1988 Naturliche und Synthetische Sexualhormone Biologische Grundlagen und Behandlungsprinzipien Natural and Synthetic Sexual Hormones Biological Basis and Medical Treatment Principles In Hermann P G Schneider Christian Lauritzen Eberhard Nieschlag eds Grundlagen und Klinik der Menschlichen Fortpflanzung Foundations and Clinic of Human Reproduction in German Walter de Gruyter pp 229 306 ISBN 978 3110109689 OCLC 35483492 Little A B amp Billiar R B 1983 Progestagens In Endocrinology of Pregnancy 3rd Edition pp 92 111 Harper and Row Philadelphia https scholar google com scholar cluster 2512291948467467634 a b c d e f g h i Progesterone Reference Ranges Performed at the Clinical Center at the National Institutes of Health Bethesda MD 03Feb09 a b c d e f g h Converted from mass values using molar mass of 314 46 g mol Haggstrom M 2014 Reference ranges for estradiol progesterone luteinizing hormone and follicle stimulating hormone during the menstrual cycle WikiJournal of Medicine 1 1 doi 10 15347 wjm 2014 001 ISSN 2002 4436 S2CID 88035135 Goodson III WH Handagama P Moore II DH Dairkee S 13 December 2007 Milk products are a source of dietary progesterone 30th Annual San Antonio Breast Cancer Symposium pp abstract 2028 Retrieved 12 March 2008 Pauli GF Friesen JB Godecke T Farnsworth NR Glodny B March 2010 Occurrence of progesterone and related animal steroids in two higher plants Journal of Natural Products 73 3 338 345 doi 10 1021 np9007415 PMID 20108949 S2CID 26467578 Applezweig N May 1969 Steroids Chemical Week 104 57 72 PMID 12255132 Noguchi E Fujiwara Y Matsushita S Ikeda T Ono M Nohara T September 2006 Metabolism of tomato steroidal glycosides in humans Chemical amp Pharmaceutical Bulletin 54 9 1312 1314 doi 10 1248 cpb 54 1312 PMID 16946542 Yang DJ Lu TJ Hwang LS October 2003 Isolation and identification of steroidal saponins in Taiwanese yam cultivar Dioscorea pseudojaponica Yamamoto PDF Journal of Agricultural and Food Chemistry 51 22 6438 6444 doi 10 1021 jf030390j PMID 14558759 Final report of the amended safety assessment of Dioscorea Villosa Wild Yam root extract International Journal of Toxicology 23 Suppl 2 49 54 2004 doi 10 1080 10915810490499055 PMID 15513824 S2CID 962216 Nino J Jimenez DA Mosquera OM Correa YM 2007 Diosgenin quantification by HPLC in a Dioscorea polygonoides tuber collection from colombian flora Journal of the Brazilian Chemical Society 18 5 1073 1076 doi 10 1590 S0103 50532007000500030 S2CID 95193700 Myoda T Nagai T Nagashima T 2005 Properties of starches in yam Dioscorea spp tuber Current Topics in Food Science and Technology 105 114 ISBN 81 308 0003 9 Wesp LM Deutsch MB March 2017 Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons The Psychiatric Clinics of North America 40 1 99 111 doi 10 1016 j psc 2016 10 006 PMID 28159148 Dolitsky SN Cordeiro Mitchell CN Stadler SS Segars JH November 2020 Efficacy of progestin only treatment for the management of menopausal symptoms a systematic review Menopause 28 2 217 224 doi 10 1097 GME 0000000000001676 PMID 33109992 S2CID 225100434 Ruan X Mueck AO November 2014 Systemic progesterone therapy oral vaginal injections and even transdermal Maturitas 79 3 248 255 doi 10 1016 j maturitas 2014 07 009 PMID 25113944 Filicori M November 2015 Clinical roles and applications of progesterone in reproductive medicine an overview Acta Obstetricia et Gynecologica Scandinavica 94 Suppl 161 3 7 doi 10 1111 aogs 12791 PMID 26443945 Ciampaglia W Cognigni GE November 2015 Clinical use of progesterone in infertility and assisted reproduction Acta Obstetricia et Gynecologica Scandinavica 94 Suppl 161 17 27 doi 10 1111 aogs 12770 PMID 26345161 S2CID 40753277 Choi SJ September 2017 Use of progesterone supplement therapy for prevention of preterm birth review of literatures Obstetrics amp Gynecology Science 60 5 405 420 doi 10 5468 ogs 2017 60 5 405 PMC 5621069 PMID 28989916 Coomarasamy A Harb HM Devall AJ Cheed V Roberts TE Goranitis I et al June 2020 Progesterone to prevent miscarriage in women with early pregnancy bleeding the PRISM RCT Health Technology Assessment 24 33 1 70 doi 10 3310 hta24330 PMC 7355406 PMID 32609084 a b Elks J 14 November 2014 The Dictionary of Drugs Chemical Data Chemical Data Structures and Bibliographies Springer pp 1024 ISBN 978 1 4757 2085 3 a b Index Nominum 2000 International Drug Directory Taylor amp Francis January 2000 pp 880 ISBN 978 3 88763 075 1 Numazawa M Nagaoka M Kunitama Y September 1986 Regiospecific deoxygenation of the dihydroxyacetone moiety at C 17 of corticoid steroids with iodotrimethylsilane Chemical amp Pharmaceutical Bulletin 34 9 3722 3726 doi 10 1248 cpb 34 3722 PMID 3815593 a b Marker RE Krueger J 1940 Sterols CXII Sapogenins XLI The Preparation of Trillin and its Conversion to Progesterone J Am Chem Soc 62 12 3349 3350 doi 10 1021 ja01869a023 Goswami A Kotoky R Rastogi RC Ghosh AC 1 May 2003 A One Pot Efficient Process for 16 Dehydropregnenolone Acetate Organic Process Research amp Development 7 3 306 308 doi 10 1021 op0200625 Heyl FW 1950 Progesterone from 3 Acetoxybisnor 5 cholenaldehyde and 3 Ketobisnor 4 cholenaldehyde Journal of the American Chemical Society 72 6 2617 2619 doi 10 1021 ja01162a076 Slomp G 1958 Ozonolysis II 1 The Effect of Pyridine on the Ozonolysis of 4 22 Stigmastadien 3 one 2 Journal of the American Chemical Society 80 4 915 921 doi 10 1021 ja01537a041 Sundararaman P Djerassi C October 1977 A convenient synthesis of progesterone from stigmasterol The Journal of Organic Chemistry 42 22 3633 3634 doi 10 1021 jo00442a044 PMID 915584 Nova Transcripts Forgotten Genius PBS org 6 February 2007 Giants of the Past lipidlibrary aocs org Archived from the original on 15 April 2012 a b c Johnson WS Gravestock MB McCarry BE August 1971 Acetylenic bond participation in biogenetic like olefinic cyclizations II Synthesis of dl progesterone Journal of the American Chemical Society 93 17 4332 4334 doi 10 1021 ja00746a062 PMID 5131151 Corner GW Allen WM 1 March 1929 Physiology of the corpus luteum American Journal of Physiology Legacy Content 88 2 326 339 doi 10 1152 ajplegacy 1929 88 2 326 ISSN 0002 9513 a b c Coutinho EM Segal SJ 1999 Is Menstruation Obsolete Oxford University Press pp 31 ISBN 978 0 19 513021 8 Walker A 7 March 2008 The Menstrual Cycle Routledge pp 49 ISBN 978 1 134 71411 7 Piosik R 2003 Adolf Butenandt und sein Wirken an der Technischen Hochschule Danzig Chemkon 10 3 135 138 doi 10 1002 ckon 200390038 Ginsburg B 6 December 2012 Premenstrual Syndrome Ethical and Legal Implications in a Biomedical Perspective Springer Science amp Business Media pp 274 ISBN 978 1 4684 5275 4 Rolleston HD 1936 The Endocrine Organs in Health and Disease With an Historical Review Oxford University Press H Milford p 406 Allen WM October 1970 Progesterone how did the name originate Southern Medical Journal 63 10 1151 1155 doi 10 1097 00007611 197010000 00012 PMID 4922128 S2CID 35867375 Refsal K February 2009 Interpretation of Serum Progesterone Results for Management of Breeding in Dogs PDF Webcd endo ref Progesterone Prices Coupons amp Savings Tips GoodRx www goodrx com Retrieved 1 August 2023 Progesterone Prices Coupons amp Savings Tips GoodRx www goodrx com Retrieved 1 August 2023 External links editProgesterone MS Spectrum Progesterone at the U S National Library of Medicine Medical Subject Headings MeSH Kimball JW 27 May 2007 Progesterone Kimball s Biology Pages Archived from the original on 18 June 2008 Retrieved 18 June 2008 Retrieved from https en wikipedia org w index php title Progesterone amp oldid 1204009599, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.